<SEC-DOCUMENT>0001193125-21-236306.txt : 20210804
<SEC-HEADER>0001193125-21-236306.hdr.sgml : 20210804
<ACCEPTANCE-DATETIME>20210804161443
ACCESSION NUMBER:		0001193125-21-236306
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20210803
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210804
DATE AS OF CHANGE:		20210804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avidity Biosciences, Inc.
		CENTRAL INDEX KEY:			0001599901
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461336960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39321
		FILM NUMBER:		211144191

	BUSINESS ADDRESS:	
		STREET 1:		10975 N. TORREY PINES RD.,
		STREET 2:		#150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-401-7900

	MAIL ADDRESS:	
		STREET 1:		10975 N. TORREY PINES RD.,
		STREET 2:		#150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avidity Biosciences LLC
		DATE OF NAME CHANGE:	20161227

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avidity NanoMedicines LLC
		DATE OF NAME CHANGE:	20140211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d171991d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rna="http://www.aviditybiosciences.com/20210803" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-08-03_to_2021-08-03">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-08-03_to_2021-08-03">0001599901</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="rna-20210803.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-08-03_to_2021-08-03"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001599901</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-03</xbrli:startDate> <xbrli:endDate>2021-08-03</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-08-03_to_2021-08-03">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt:datemonthdayyearen">August&#160;3, 2021</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-08-03_to_2021-08-03">AVIDITY BIOSCIENCES, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-08-03_to_2021-08-03">001-39321</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-08-03_to_2021-08-03">46-1336960</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-08-03_to_2021-08-03">10975 N. Torrey Pines Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-08-03_to_2021-08-03">Suite 150</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-08-03_to_2021-08-03">La Jolla</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-08-03_to_2021-08-03">92037</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip Code)</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-08-03_to_2021-08-03">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-08-03_to_2021-08-03">401-7900</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, include area code)</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-08-03_to_2021-08-03">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-08-03_to_2021-08-03">RNA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2021-08-03_to_2021-08-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;3, 2021, Avidity Biosciences, Inc. (&#8220;Avidity&#8221; or the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Cowen and Company, LLC, SVB Leerink LLC, Evercore Group L.L.C. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to the issuance and sale of 8,000,000 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;). The price to the public in this offering is $18.00 per share. The Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $16.92 per share. The net proceeds to the Company from this offering are expected to be approximately $135.0&#160;million, or approximately $155.3&#160;million if the Underwriters&#8217; option to purchase additional shares is exercised in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering is expected to close on August&#160;6, 2021, subject to the satisfaction of customary closing conditions. In addition, under the terms of the Underwriting Agreement, the Company has granted the Underwriters a <span style="white-space:nowrap">30-day</span> option to purchase up to 1,200,000 additional shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering is being made pursuant to the Company&#8217;s shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration Statement <span style="white-space:nowrap">No.&#160;333-257691)</span> which became automatically effective upon filing with the Securities and Exchange Commission (the &#8220;SEC&#8221;), and prospectus supplement and accompanying prospectus filed with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed as Exhibit 1.1 to this report and is incorporated by reference herein. A copy of the opinion of Latham&#160;&amp; Watkins LLP relating to the legality of the issuance and sale of Common Stock in the offering is attached as Exhibit 5.1 to this report. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company issued press releases on August&#160;2, 2021 and August&#160;3, 2021 announcing the commencement and pricing of the offering, respectively, which press releases are attached as Exhibits 99.1 and 99.2, respectively, to this report. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding the completion of the offering and the expected net proceeds therefrom. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in Avidity&#8217;s business, including those described in the Company&#8217;s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Avidity undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section&#160;21E of the Private Securities Litigation Reform Act of 1995. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d171991dex11.htm">Underwriting Agreement, dated August&#160;3, 2021, by and among Avidity Biosciences, Inc. and Cowen and Company, LLC, SVB Leerink LLC, Evercore Group L.L.C., and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d171991dex51.htm">Opinion of Latham&#160;&amp; Watkins LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d171991dex51.htm">Consent of Latham&#160;&amp; Watkins LLP (included in Exhibit 5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d171991dex991.htm">Press Release dated August&#160;2, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d171991dex992.htm">Press Release dated August&#160;3, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap">AVIDITY BIOSCIENCES, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: August&#160;4, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael F. MacLean</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Michael F. MacLean</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d171991dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8,000,000 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AVIDITY BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">August&nbsp;3, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C<SMALL>OWEN</SMALL>
<SMALL>AND</SMALL> C<SMALL>OMPANY</SMALL>, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB L<SMALL>EERINK</SMALL> LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E<SMALL>VERCORE</SMALL> G<SMALL>ROUP</SMALL> L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">W<SMALL>ELLS</SMALL> F<SMALL>ARGO</SMALL> S<SMALL>ECURITIES</SMALL>, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cowen and Company, LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10022 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SVB Leerink LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">53 State Street, 40th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evercore Group L.L.C. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10055 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wells Fargo Securities, LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">500 West 33rd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10001 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs and Madams: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;I<SMALL>NTRODUCTORY</SMALL>. Avidity Biosciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to sell,
pursuant to the terms of this Agreement, to the several underwriters named in <U>Schedule A</U> hereto (the &#147;<B>Underwriters</B>,&#148; or, each, an &#147;<B>Underwriter</B>&#148;), an aggregate of 8,000,000 shares of common stock, $0.0001 par
value per share (the &#147;<B>Common Stock</B>&#148;) of the Company. The aggregate of 8,000,000 shares so proposed to be sold is hereinafter referred to as the &#147;<B>Firm Stock</B>&#148;. The Company also proposes to sell to the Underwriters,
upon the terms and conditions set forth in Section&nbsp;3 hereof, up to an additional 1,200,000 shares of Common Stock (the &#147;<B>Optional Stock</B>&#148;). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the
&#147;<B>Stock</B>&#148;. Cowen and Company, LLC, SVB Leerink LLC, Evercore Group L.L.C. and Wells Fargo Securities, LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the
&#147;<B>Representatives</B>.&#148; In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to &#147;subsidiaries&#148; of the Company shall be deemed to refer to no subsidiary, or such single
subsidiary, <I>mutatis mutandis</I>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMPANY</SMALL>. The Company represents and warrants to the several Underwriters, as of the date hereof and as of each Closing Date (as defined below), and agrees with the several Underwriters, that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Automatic Shelf Registration Statement</U>. An &#147;automatic shelf registration statement&#148;
as defined in Rule 405 of the Rules and Regulations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT> 257691) in respect of the Stock has been filed with the Securities and Exchange
Commission (the &#147;<B>Commission</B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), and the rules and regulations of the Commission thereunder (the &#147;<B>Rules and Regulations</B>&#148;), not
earlier than three (3)&nbsp;years prior to the date hereof; such registration statement, and any post-effective amendment thereto, became effective on filing; and no stop order suspending the effectiveness of such registration statement or any part
thereof has been issued and no proceeding for that purpose has been initiated or threatened by the Commission, and no notice of objection of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to
Rule 401(g)(2) of the Rules and Regulations has been received by the Company (the prospectus filed as part of such automatic shelf registration statement in the form in which it has most recently been filed with the Commission on or prior to the
date of this Agreement, is hereinafter called the &#147;<B>Base Prospectus</B>&#148; and any preliminary prospectus (including any preliminary prospectus supplement) relating to the Stock filed with the Commission pursuant to Rule 424(b) of the
Rules and Regulations is hereinafter called a &#147;<B>Preliminary Prospectus</B>&#148;). Such automatic shelf registration statement, including all exhibits thereto, but excluding Form <FONT STYLE="white-space:nowrap">T-1,</FONT> and including any
prospectus supplement relating to the Stock that is filed with the Commission and deemed by virtue of Rule 430B of the Rules and Regulations to be part of such automatic shelf registration statement, are hereinafter collectively called the
&#147;<B>Registration Statement</B>.&#148; The form of the final prospectus relating to the Stock filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations in accordance with Section&nbsp;4(i)(a) hereof, is hereinafter called
the &#147;<B>Prospectus</B>.&#148; Any reference herein to the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein; any reference to any amendment or
supplement to the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any post-effective amendment to the Registration Statement, any prospectus supplement relating to the Stock filed with the
Commission pursuant to Rule 424(b) of the Rules and Regulations and any documents filed under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and incorporated by reference therein, in each case after the date
of the Base Prospectus, such Preliminary Prospectus, or Prospectus, as the case may be; any reference to any amendment to the Registration Statement shall be deemed to refer to and include any annual report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> of the Company filed pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act after the effective date of the Registration Statement that is incorporated by reference into the Registration Statement,
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>General Disclosure Package</U>. As of the Applicable Time (as defined below) and as of the
Closing Date or the Option Closing Date (as defined below), as the case may be, neither (i)&nbsp;the General Use Free Writing Prospectus(es) (as defined below) issued at or prior to the Applicable Time, the Pricing Prospectus (as defined below) and
the information included on <U>Schedule C</U> hereto, all considered together (collectively, the &#147;<B>General Disclosure Package</B>&#148;), (ii) any individual Limited Use Free Writing Prospectus (as defined below), (iii) the bona fide
electronic roadshow (as defined in Rule 433(h)(5) of the Rules and Regulations), nor (iv)&nbsp;any individual Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication (as defined
below), when considered together with the General Disclosure Package, included or will include any untrue statement of a material fact or omitted or will omit to state a material fact necessary in order to make the statements therein, in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no representations or warranties as to information contained in or omitted
from the Pricing Prospectus or any Issuer Free Writing Prospectus (as defined below), in reliance upon, and in conformity with, written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically
for inclusion therein, which information the parties hereto agree is limited to the Underwriter&#146;s Information (as defined in Section&nbsp;18). As used in this paragraph (b)&nbsp;and elsewhere in this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Time</B>&#148; means 7:00 P.M., New York time, on the date of this Agreement or such other time as agreed to by the
Company and the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pricing Prospectus</B>&#148; means the Base Prospectus, as amended and supplemented immediately
prior to the Applicable Time, including any document incorporated by reference therein and any prospectus supplement deemed to be a part thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuer Free Writing Prospectus</B>&#148; means any &#147;issuer free writing prospectus,&#148; as defined in Rule 433 of the Rules
and Regulations relating to the Stock in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule 433(g) of the Rules and Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>General Use Free Writing Prospectus</B>&#148; means any Issuer Free Writing Prospectus that is identified on <U>Schedule B</U> to
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Limited Use Free Writing Prospectuses</B>&#148; means any Issuer Free Writing Prospectus that is not a General
Use Free Writing Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication (as
defined below) that is a written communication within the meaning of Rule 405 of the Rules and Regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Stop Orders; No Material Misstatements</U>. No order preventing or suspending the use of any
Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus relating to the proposed offering of the Stock has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act
has been instituted or, to the Company&#146;s knowledge, threatened by the Commission, and each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Securities Act and the Rules and
Regulations, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading; provided, however, that the Company makes no representations or warranties as to information contained in or omitted from any Preliminary Prospectus, in reliance upon, and in conformity with, written information furnished to the Company
through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriter&#146;s Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Statement and Prospectus Contents</U>. At the respective times, the Registration
Statement and any amendments thereto became or become effective as to the Underwriters and at each Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the
Securities Act and the Rules and Regulations and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at each Closing Date,
conformed and will conform in all material respects to the requirements of the Securities Act and the Rules and Regulations and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that the foregoing representations and warranties in this paragraph (d)&nbsp;shall not apply to information contained in or
omitted from the Registration Statement or the Prospectus, or any amendment or supplement thereto, in reliance upon, and in conformity with, written information furnished to the Company through the Representatives by or on behalf of any Underwriter
specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriter&#146;s Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuer Free Writing Prospectus</U>. Each Issuer Free Writing Prospectus, as of its issue date and
at all subsequent times through the completion of the public offer and sale of the Stock or until any earlier date that the Company notified or notifies the Representatives as described in Section&nbsp;4(i)(g), did not, does not and will not include
any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus, including any document incorporated by reference therein and any prospectus
supplement deemed to be a part thereof, that has not been superseded or modified, or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact required to be stated therein or necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading, provided, however, that the foregoing representations and warranties in this paragraph (e)&nbsp;shall not apply to information
contained in or omitted from the Registration Statement or the Prospectus, or any amendment or supplement thereto, in reliance upon, and in conformity with, written information furnished to the Company through the Representatives by or on behalf of
any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriter&#146;s Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents Incorporated by Reference</U>. The documents incorporated by reference in the
Prospectus, when they were filed with the Commission conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the Rules and Regulations and none of such documents contained any untrue
statement of a material fact or omitted to state any material fact required to be stated therein, or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so
filed and incorporated by reference in the Prospectus, when such documents are filed with Commission will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the Rules and Regulations
and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Distribution of Offering Materials</U>. The Company has not, directly or indirectly,
distributed and will not distribute any offering material in connection with the offering and sale of the Stock other than any Preliminary Prospectus, the Prospectus and other materials, if any, permitted under the Securities Act and consistent with
Section&nbsp;4(i)(b) below. The Company will file with the Commission all Issuer Free Writing Prospectuses (other than a &#147;road show&#148; as described in Rule 433(d)(8) of the Rules and Regulations) in the time and manner required under Rules
163(b)(2) and 433(d) of the Rules and Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Emerging Growth Company</U>. From the
first date on which the Company engaged directly or through any person authorized to act on its behalf in any communication in reliance on Section&nbsp;5(d) of the Securities Act through the date hereof, the Company has been and is an &#147;emerging
growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;<B>Emerging Growth Company</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Not an Ineligible Issuer</U>. (A)&nbsp;At the
time of filing the Initial Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendments thereto, and at the date hereof, the Company was not, and the Company currently is not, an &#147;ineligible issuer,&#148; as
defined in Rule 405 of the Rules and Regulations and (B)(i) at the time of the filing of the Registration Statement, (ii)&nbsp;at the time of the most recent amendment thereto for the purpose of complying with Section&nbsp;10(a)(3) of the Securities
Act (whether such amendment was by post-effective amendment, an incorporated report filed pursuant to Section&nbsp;1 or 15(d) of the Exchange Act or form of prospectus), and (iii)&nbsp;at the time the Company or any person acting on its behalf
(within the meaning, for this clause only, of Rule 163(c) of the Rules and Regulations) made any offer relating to the Stock in reliance on the exemption of Rule 163 of the Rules and Regulations, the Company was a &#147;well-known seasoned
issuer&#148; as defined in Rule 405 of the Rules and Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications</U>. The Company (a)&nbsp;has not alone engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the
consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and
(b)&nbsp;has not authorized anyone other than the Representatives to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the Representatives have
been authorized to act on its behalf in undertaking <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than those listed on <U>Schedule D</U> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization and Good Standing</U>. The Company and each of its subsidiaries (as defined in
Section&nbsp;16) have been duly organized and are validly existing as corporations or other legal entities in good standing (or the foreign equivalent thereof) under the laws of their respective jurisdictions of organization. The Company and each of
its subsidiaries are duly qualified to do business and are in good standing as foreign corporations or other legal entities in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses
requires such qualification and have all power and authority (corporate or other) necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to so qualify or have such power
or authority would not reasonably be expected to (i)&nbsp;have, singly or in the aggregate, a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the
Company and its subsidiaries taken as a whole, or (ii)&nbsp;impair in any material respect the ability of the Company to perform its obligations under this Agreement or to consummate any transactions contemplated by this Agreement, the General
Disclosure Package or the Prospectus (any such effect as described in clauses (i)&nbsp;or (ii), a &#147;<B>Material Adverse Effect</B>&#148;). The Company has no subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriting Agreement</U>. This Agreement has been duly authorized, executed and delivered by
the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>The Stock</U>. The Stock to be issued and sold by the Company to the
Underwriters hereunder has been duly and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully paid, <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and will
conform to the descriptions thereof in the Registration Statement, the General Disclosure Package and the Prospectus; and the issuance of the Stock is not subject to any preemptive or similar rights that have not been complied with or otherwise
validly waived. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>. The Company has an
authorized capitalization as set forth under the heading &#147;Capitalization&#148; in the Pricing Prospectus, and all of the issued shares of capital stock of the Company, have been duly and validly authorized and issued, are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and not subject to any preemptive or similar rights that have not been complied with or otherwise validly waived, have been issued in compliance with federal and state securities laws, and conform in
all material respects to the description thereof contained in the General Disclosure Package and the Prospectus. All of the Company&#146;s options, warrants and other rights to purchase or exchange any securities for shares of the Company&#146;s
capital stock have been duly authorized and validly issued and were issued in compliance with federal and state securities laws. None of the outstanding shares of Common Stock were issued in violation of any preemptive rights, rights of first
refusal or other similar rights to subscribe for or purchase securities of the Company. As of the date set forth in the General Disclosure Package, there were no authorized or outstanding shares of capital stock, options, warrants, preemptive
rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described above or accurately
described in the General Disclosure Package. Since such date, the Company has not issued any securities other than Common Stock issued pursuant to the exercise of warrants or upon the exercise of stock options or other awards outstanding under the
Company&#146;s stock option plans, options or other securities granted or issued pursuant to the Company&#146;s existing equity compensation plans or other plans, and the issuance of Common Stock pursuant to employee stock purchase plans. The
description of the Company&#146;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, as described in the General Disclosure Package and the Prospectus, accurately and fairly present
in all material respects the information required to be shown with respect to such plans, arrangements, options and rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Conflicts</U>. The execution, delivery and performance of this Agreement by the Company, the
issue and sale of the Stock by the Company and the consummation of the transactions contemplated hereby will not (with or without notice or lapse of time or both)&nbsp;(i) conflict with or result in a breach or violation of any of the terms or
provisions of, constitute a default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, encumbrance, security interest, claim or charge upon any property or assets of the Company or any
subsidiary pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of
the property or assets of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or analogous governing instruments, as applicable) of
the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law, statute, rule, regulation, judgment, order or decree of any court or governmental or regulatory agency or body, domestic or foreign, having jurisdiction over
the Company or any of its subsidiaries or any of their properties or assets except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation or default that would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. A &#147;<B>Debt Repayment Triggering Event</B>&#148; means any event or condition that gives, or with the giving of notice or lapse of time would give the holder of any note, debenture or other evidence of
indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company of any of its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Consents Required</U>. Except for the
registration of the Stock under the Securities Act and applicable state securities laws, and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc.
(&#147;<B>FINRA</B>&#148;) and the Nasdaq Global Market (the &#147;<B>Exchange</B>&#148;) in connection with the purchase and distribution of the Stock by the Underwriters and the listing of the Stock on the Exchange, no consent, approval,
authorization or order of, or filing, qualification or registration (each an &#147;<B>Authorization</B>&#148;) with, any court, governmental or regulatory agency or body, foreign or domestic, which has not been made, obtained or taken and is not in
full force and effect, is required for the execution, delivery and performance of this Agreement by the Company, the issuance and sale of the Stock or the consummation of the transactions contemplated hereby; and no event has occurred that allows or
results in, or after notice or lapse of time or both would allow or result in, revocation, suspension, termination or invalidation of any such Authorization or any other impairment of the rights of the holder or maker of any such Authorization. All
corporate approvals (including those of stockholders) necessary for the Company to consummate the transactions contemplated by this Agreement have been obtained and are in effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent Auditors</U>. BDO USA, LLP, who have certified certain financial statements of the
Company and its subsidiaries included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, is an independent registered public accounting firm with respect to the Company and its subsidiaries
within the meaning of Article <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> and the Public Company Accounting Oversight Board (United States) (the &#147;<B>PCAOB</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial Statements</U>. The financial statements, together with the related notes, included or
incorporated by reference in the General Disclosure Package, the Prospectus and in the Registration Statement fairly present, in all material respects, the financial position and the results of operations and changes in financial position of the
Company and its consolidated subsidiaries at the respective dates or for the respective periods therein specified. Such statements and related notes have been prepared in accordance with the generally accepted accounting principles in the United
States (&#147;<B>GAAP</B>&#148;) applied on a consistent basis throughout the periods involved except as may be set forth in the related notes included or incorporated by reference in the General Disclosure Package and provided that unaudited
interim financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments, may not contain certain footnotes, as permitted by the rules of the Commission. The financial statements, together with the
related notes, included or incorporated by reference in the General Disclosure Package and the Prospectus comply in all material respects with Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> No other financial statements or supporting
schedules or exhibits are required by Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> to be described, included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus. The pro forma
financial information included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus have been properly compiled and prepared in all material respects in accordance with the applicable
requirements of Rule <FONT STYLE="white-space:nowrap">11-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> and present fairly the information shown therein, and the assumptions used in the preparation thereof are reasonable and the
adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. The summary and selected financial data included or incorporated by reference in the General Disclosure Package, the Prospectus and
the Registration Statement fairly present in all material respects the information shown therein at the respective dates and for the respective periods specified and are derived from the consolidated financial statements set forth in the
Registration Statement, the Pricing Prospectus and the Prospectus and other financial information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<U>eXtensible Business Reporting Language</U>. The interactive data in eXtensible Business Reporting
Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Material Adverse Change</U>. Neither the
Company nor any of its subsidiaries has sustained, since the date of the latest audited financial statements included or incorporated by reference in the General Disclosure Package, (i)&nbsp;any material loss or interference with its business from
fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or action, order or decree of any court or governmental or regulatory authority, otherwise than as set forth or contemplated in the General
Disclosure Package; (ii)&nbsp;any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity
incentive plans described in, the Registration Statement, the General Disclosure Package and the Prospectus) or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment,
paid or made by the Company on any class of capital stock, or any material adverse changes, or any development involving a prospective material adverse change, in or affecting the business, properties, assets, general affairs, management, financial
position, prospects, stockholders&#146; equity or results of operations of the Company and its subsidiaries taken as a whole, otherwise than as set forth or contemplated in the General Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;<U>Legal Proceedings</U>. There is no legal or governmental proceeding to which the Company or any
of its subsidiaries is a party or of which any property or assets of the Company or any of its subsidiaries is the subject, including any proceeding before the United States Food and Drug Administration of the U.S. Department of Health and Human
Services (the &#147;<B>FDA</B>&#148;) or comparable federal, state, local or foreign governmental bodies (it being understood that the interaction between the Company and the FDA and such comparable governmental bodies relating to the clinical
development and product approval process shall not be deemed proceedings for purposes of this representation), which is required to be described in the Registration Statement, the General Disclosure Package or the Prospectus or a document
incorporated by reference therein and is not described therein, or which, singly or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect, and no such
proceedings, to the Company&#146;s knowledge, are threatened by governmental or regulatory authorities or threatened by others. The Company is in compliance with all applicable federal, state, local and foreign laws, regulations, orders and decrees
governing its business as prescribed by the FDA, or any other federal, state or foreign agencies or bodies engaged in the regulation of drug products, except where failures to so comply would not, singly or in the aggregate, reasonably be expected
to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental
or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal healthcare
program or human clinical research or, to the Company&#146;s knowledge, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Violation or Default</U>. Neither the Company nor any of its subsidiaries is (i)&nbsp;in
violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or analogous governing instrument, as applicable), (ii) in default in any respect, and no event has occurred which, with notice or lapse of time or both, would constitute
such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it is bound or to
which any of its property or assets is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
subject or (iii)&nbsp;in violation in any respect of any law, ordinance, governmental rule, regulation or court order, decree or judgment to which it or its property or assets may be subject
except, in the case of clauses (ii)&nbsp;and (iii) above, for any such violation or default that would not, singly or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&nbsp;&nbsp;&nbsp;&nbsp;<U>Licenses or Permits</U>. The Company and each of its subsidiaries possess all licenses,
certificates, authorizations and permits issued by, and have made all declarations and filings with, the appropriate local, state, federal or foreign governmental or regulatory agencies or bodies (including, without limitation, those administered by
the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) that are necessary for the lease of their respective properties or the conduct of their respective
businesses as described in the Registration Statement, the General Disclosure Package and the Prospectus (collectively, the &#147;<B>Governmental Permits</B>&#148;) except where any failures to possess or make the same would not, singly or in the
aggregate, reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries are in compliance with all such Governmental Permits, except where noncompliance would not reasonably be expected to have a Material Adverse
Effect, and all such Governmental Permits are valid and in full force and effect, except where the invalidity or failure to be in full force and effect would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect.
Neither the Company nor any subsidiary has received written, and to the Company&#146;s knowledge, oral, notification of any revocation, modification, suspension, termination or invalidation (or proceedings related thereto) of any such Governmental
Permit and the Company has no reason to believe that any such Governmental Permit will not be renewed, except for such revocations, modifications, suspensions, terminations or invalidations which would not, singly or in the aggregate, reasonably be
expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;<U>Preclinical Studies</U>. The preclinical studies
conducted by or on behalf of the Company that are described in the General Disclosure Package and the Prospectus (the &#147;<B>Company Studies</B>&#148;) were and, if still pending, are being, conducted in all material respects with all applicable
federal, state and foreign laws, rules, orders and regulations; the descriptions of the results of the Company Studies contained in the Registration Statement, General Disclosure Package and Prospectus are accurate in all material respects; the
Company has no knowledge of any other studies or tests not described in the Registration Statement, the General Disclosure Package and the Prospectus, the results of which are inconsistent with or call in question the results described or referred
to in the Registration Statement, General Disclosure Package and the Prospectus; and the Company has not received any written notices or correspondence with the FDA or any foreign, state or local governmental body exercising comparable authority
requiring the termination, suspension or material modification of any Company Studies; except for such terminations, suspensions or material modifications which would not reasonably be expected to have a Material Adverse Effect and, to the
Company&#146;s knowledge, there are no reasonable grounds for the same. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Compliance</U>. The Company has not, since April&nbsp;1, 2017, received any written notice of adverse filing, warning letter, untitled letter or other written correspondence or written notice from the FDA, or any other court or arbitrator or
federal, state, local, or foreign governmental or regulatory authority, alleging or asserting material noncompliance with the Federal Food, Drug and Cosmetic Act (21 U.S.C. &#167; 301 et seq.) (the &#147;<B>FDCA</B>&#148;). Except as would not,
singly or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company and, to the Company&#146;s knowledge, its directors, officers, employees and agents is and have been, since April&nbsp;1, 2017, in material compliance
with applicable health care laws, including without limitation, the FDCA, the federal Anti-Kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), the
criminal False Claims Law (42 U.S.C. &#167; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> the Civil Monetary Penalties Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the Health Insurance Portability and
Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. &#167; 17921 et seq.) the exclusion laws (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7),</FONT> Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), the Physician Payments Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT>
and the regulations promulgated pursuant to such laws, and comparable state and foreign laws (collectively, &#147;<B>Health Care Laws</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment Company Act</U>. Neither the Company nor any of its subsidiaries is or, after giving
effect to the offering of the Stock and the application of the proceeds thereof as described in the General Disclosure Package and the Prospectus, will be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148;
by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Stabilization</U>. Neither the Company nor, to the Company&#146;s knowledge, any of its
officers, directors or affiliates has taken or will take, directly or indirectly, any action designed or intended to stabilize or manipulate the price of any security of the Company, or which caused or resulted in, or which might in the future
reasonably be expected to cause or result in, stabilization or manipulation of the price of any security of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual Property</U>. The Company and its subsidiaries own or possess the valid right to
use all (i)&nbsp;patents, patent applications, trademarks, trademark registrations, service marks, service mark registrations, Internet domain name registrations, copyrights, copyright registrations, licenses, trade secret rights
(&#147;<B>Intellectual Property Rights</B>&#148;) and (ii)&nbsp;inventions, software, works of authorships, trademarks, service marks, trade names, databases, formulae, know how, Internet domain names and other intellectual property (including trade
secrets and other unpatented and/or unpatentable proprietary confidential information, systems, or procedures) (collectively, &#147;<B>Intellectual Property Assets</B>&#148;) necessary to conduct their respective businesses as currently conducted,
and as proposed to be conducted and described in the General Disclosure Package and the Prospectus. The Company and its subsidiaries have not received any opinion from their legal counsel concluding that any activities of their respective businesses
infringe, misappropriate, or otherwise violate, valid and enforceable Intellectual Property Rights of any other person, and have not received written notice of any challenge, which is to their knowledge still pending, by any other person to the
rights of the Company and its subsidiaries with respect to any Intellectual Property Rights or Intellectual Property Assets owned or used by the Company or its subsidiaries. To the Company&#146;s knowledge, the Company and its subsidiaries&#146;
respective businesses as now conducted do not give rise to any infringement of, any misappropriation of, or other violation of, any valid and enforceable Intellectual Property Rights of any other person. All licenses for the use of the Intellectual
Property Rights described in the General Disclosure Package and the Prospectus are valid, binding upon, and enforceable by or against the parties thereto in accordance to its terms. The Company has complied in all material respects with, and is not
in breach nor has received any asserted or threatened claim of breach of any Intellectual Property license, and the Company has no knowledge of any breach or anticipated breach by any other person to any Intellectual Property license. Except as
described in the General Disclosure Package, no claim has been made against the Company alleging the infringement by the Company of any patent, trademark, service mark, trade name, copyright, trade secret, license in or other intellectual property
right or franchise right of any person. The Company has taken all reasonable steps to protect, maintain and safeguard its Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements. The
consummation of the transactions contemplated by this Agreement will not result in the loss or impairment of or payment of any additional amounts with respect to, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
nor require the consent of any other person in respect of, the Company&#146;s right to own, use, or hold for use any of the Intellectual Property Rights as owned, used or held for use in the
conduct of the business as currently conducted. With respect to the use of the software in the Company&#146;s business as it is currently conducted, the Company has not experienced any material defects in such software including any material error
or omission in the processing of any transactions other than defects which have been corrected, and to the Company&#146;s knowledge, no such software contains any device or feature designed to disrupt, disable, or otherwise impair the functioning of
any software or is subject to the terms of any &#147;open source&#148; or other similar license that provides for the source code of the software to be publicly distributed or dedicated to the public. To the Company&#146;s knowledge, except as
disclosed in the General Disclosure Package, (i)&nbsp;all patents and patent applications have been properly filed and each issued patent is being diligently maintained; (ii)&nbsp;the Company has taken reasonable steps to obtain executed
nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with its employees, (iii)&nbsp;no employee of the Company is in or has been in violation of any term of any employment contract, patent
disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant to or
with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company; (iv)&nbsp;the duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of
the United States patents and patent applications included in the Intellectual Property Rights have been complied with, and in all foreign offices having similar requirements, all such requirements have been complied with; (v)&nbsp;there are no
third parties who have rights to any Intellectual Property Rights owned by the Company, except for <FONT STYLE="white-space:nowrap">non-exclusive</FONT> <FONT STYLE="white-space:nowrap">out-licenses</FONT> to such Intellectual Property granted in
the ordinary course of business; and (vi)&nbsp;there is no infringement by third parties of any Intellectual Property Rights owned or licensed to the Company; in each case that would reasonably be expected, individually or in the aggregate, to have
a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)&nbsp;&nbsp;&nbsp;&nbsp;<U>IT Systems</U>. (A)(x) To the Company&#146;s knowledge, there
has been no security breach or attack or other compromise of or relating to any of the Company&#146;s and its subsidiaries&#146; information technology and computer systems, networks, hardware, software, data (including the data of their respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment or technology (&#147;<B>IT Systems and Data</B>&#148;), and (y)&nbsp;the Company and its subsidiaries have not been notified of, and
have no knowledge of any event or condition that would reasonably be expected to result in any security breach, attack or compromise to their IT Systems and Data, (B)&nbsp;the Company and its subsidiaries have complied, and are presently in
compliance with, all applicable laws, statutes or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority and all industry guidelines, standards, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, and (C)&nbsp;the Company and its subsidiaries have implemented
commercially reasonable backup and disaster recovery technology consistent with industry standards and practice, and (D)&nbsp;neither the Company nor any of its subsidiaries (x)&nbsp;has received notice of any actual or potential liability under or
relating to any applicable law, industry guidelines, standards, internal policies and contractual obligations governing the IT Systems and Data, and (y)&nbsp;is party to any order, decree or agreement that imposed any obligations or liability under
or relating to any applicable law, industry guidelines, standards, internal policies and contractual obligations governing the IT Systems and Data. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd)&nbsp;&nbsp;&nbsp;&nbsp;<U>Title to Real and Personal Property</U>. The Company does not own any real property and the
Company and each of its subsidiaries have valid and marketable rights to lease or otherwise use, all items of real or personal property which are material to the business of the Company and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
its subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims and defects that (i)&nbsp;do not, singly or in the aggregate, materially
affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries or (ii)&nbsp;could not reasonably be expected, singly or in the aggregate, to have
a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Labor Dispute</U>. There is (A)&nbsp;no significant unfair
labor practice complaint pending against the Company, or any of its subsidiaries, nor to the Company&#146;s knowledge, threatened against it or any of its subsidiaries, before the National Labor Relations Board, any state or local labor relation
board or any foreign labor relations board, and no significant grievance or significant arbitration proceeding arising out of or under any collective bargaining agreement is so pending against the Company or any of its subsidiaries, or, to the
Company&#146;s knowledge, threatened against it and (B)&nbsp;no labor disturbance by or dispute with, employees of the Company or any of its subsidiaries exists or, to the Company&#146;s knowledge, is threatened, and the Company is not aware of any
existing or imminent labor disturbance by the employees of any of its or its subsidiaries&#146; principal suppliers, manufacturers, customers or contractors, that could reasonably be expected, singly or in the aggregate, to have a Material Adverse
Effect. The Company is not aware that any key employee or significant group of employees of the Company or any subsidiary plans to terminate employment with the Company or any such subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with ERISA</U>. No &#147;prohibited transaction&#148; (as defined in Section&nbsp;406
of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#147;<B>ERISA</B>&#148;), or Section&nbsp;4975 of the Internal Revenue Code of 1986, as amended from time to
time (the &#147;<B>Code</B>&#148;)) or &#147;accumulated funding deficiency&#148; (as defined in Section&nbsp;302 of ERISA) or any of the events set forth in Section&nbsp;4043(b) of ERISA (other than events with respect to which the thirty <FONT
STYLE="white-space:nowrap">(30)-day</FONT> notice requirement under Section&nbsp;4043 of ERISA has been waived) has occurred or could reasonably be expected to occur with respect to any employee benefit plan of the Company or any of its subsidiaries
which could, singly or in the aggregate, have a Material Adverse Effect. Each employee benefit plan of the Company or any of its subsidiaries is in compliance in all material respects with applicable law, including ERISA and the Code. The Company
and its subsidiaries have not incurred and could not reasonably be expected to incur liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any pension plan (as defined in ERISA). Each pension plan for which the
Company or any of its subsidiaries would have any liability that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and to the Company&#146;s knowledge, nothing has occurred, whether by action or by failure to act,
which could, singly or in the aggregate, reasonably be expected to cause the loss of such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental Laws and Hazardous Materials</U>. The Company and its subsidiaries are in
compliance in all material respects with all foreign, federal, state and local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the
environment which are applicable to their businesses (&#147;<B>Environmental Laws</B>&#148;). There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other
wastes or other hazardous substances by, due to, or caused by the Company or any of its subsidiaries (or, to the Company&#146;s knowledge, any other entity for whose acts or omissions the Company or any of its subsidiaries is or may otherwise be
liable) upon any of the property now or previously owned or leased by the Company or any of its subsidiaries, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which
would, under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability that could, singly or in the aggregate, reasonably be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
expected to have a Material Adverse Effect; and there has been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding such property
of any toxic or other wastes or other hazardous substances with respect to which the Company or any of its subsidiaries has knowledge. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>. The Company and its subsidiaries each (i)&nbsp;have timely filed all necessary
federal, state, local and foreign tax returns, and all such returns were true, complete and correct in all material respects, (ii)&nbsp;have paid all federal, state, local and foreign taxes, for which it is liable, including, without limitation, all
sales and use taxes and all taxes which the Company or any of its subsidiaries is obligated to withhold from amounts owing to employees, creditors and third parties, and (iii)&nbsp;do not have any tax deficiency or claims outstanding or assessed or,
to its knowledge, proposed against any of them, except those, in each of the cases described in clauses (i), (ii) and (iii)&nbsp;above, that would not, singly or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. The Company and each of its subsidiaries carry, or are covered by, insurance in
such amounts and covering such risks as the Company reasonably believes is adequate for the conduct of their respective businesses and the value of their respective properties. Neither the Company nor any of its subsidiaries has any reason to
believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material
Adverse Effect. Neither the Company nor any of its subsidiaries has received written notice from any insurer, agent of such insurer or the broker of the Company or any of its subsidiaries that any material capital improvements or any other material
expenditures (other than premium payments) are required or necessary to be made in order to continue such insurance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accounting Controls</U>. The Company and each of its subsidiaries maintains a system of
&#147;internal control over financial reporting&#148; (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the General Rules and Regulations under the Exchange Act) that complies with the requirements of the Exchange
Act and has been designed by their respective principal executive and principal financial officers, or under their supervision, to provide reasonable assurances that (i)&nbsp;transactions are executed in accordance with management&#146;s general or
specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance
with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and
(v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the Commission&#146;s rules and guidelines applicable thereto. The Company&#146;s internal
control over financial reporting is effective. Except as described in the General Disclosure Package, since the end of the Company&#146;s most recent audited fiscal year, there has been (A)&nbsp;no material weakness in the Company&#146;s internal
control over financial reporting (whether or not remediated) and (B)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure Controls</U>. The Company and its
subsidiaries maintain disclosure controls and procedures (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act Rules) that comply with the requirements of the Exchange Act; such disclosure controls
and procedures have been designed to ensure that information required to be disclosed by the Company and its subsidiaries in reports that they file or submit under the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
communicated to the Company&#146;s management to allow timely decisions regarding disclosures. The Company and its subsidiaries have conducted evaluations of the effectiveness of their disclosure
controls as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)&nbsp;&nbsp;&nbsp;&nbsp;<U>Minute Books</U>. The minute books of the Company and each of its subsidiaries have been made
available to the Underwriters and counsel for the Underwriters, and such books (i)&nbsp;contain a complete summary of all meetings and actions of the board of directors (including each board committee) and stockholders of the Company (or analogous
governing bodies and interest holders, as applicable), and each of its subsidiaries since the time of its respective incorporation or organization through the date of the latest meeting and action, and (ii)&nbsp;accurately in all material respects
reflect all transactions referred to in such minutes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Undisclosed Relationships</U>. No
relationship, direct or indirect, exists between or among the Company or any of its subsidiaries on the one hand, and the directors, officers, stockholders (or analogous interest holders), customers or suppliers of the Company or any of its
affiliates on the other hand, which is required to be described in the General Disclosure Package and the Prospectus or a document incorporated by reference therein and which is not so described. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Registration Rights</U>. No person or entity has the right to require registration of shares
of Common Stock or other securities of the Company or any of its subsidiaries because of the filing or effectiveness of the Registration Statement or otherwise, except for persons and entities who have expressly waived such right in writing or who
have been given timely and proper written notice and have failed to exercise such right within the time or times required under the terms and conditions of such right. Except as described in the General Disclosure Package, there are no persons with
registration rights or similar rights to have any securities registered by the Company or any of its subsidiaries under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo)&nbsp;&nbsp;&nbsp;&nbsp;<U>Margin Rules</U>. The application of the proceeds received by the Company from the issuance,
sale and delivery of the Stock as described in the General Disclosure Package and the Prospectus will not violate Regulation T, U or X of the Board of Governors of the Federal Reserve system or any other regulation of such Board of Governors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Broker&#146;s Fees</U>. Neither the Company nor any of its subsidiaries is a party to any
contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or the Underwriters for a brokerage commission, finder&#146;s fee or like payment
in connection with the offering and sale of the Stock or any transaction contemplated by this Agreement, the Registration Statement, the General Disclosure Package or the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Restrictions on Subsidiaries</U>. Except as described in the General Disclosure Package and
the Prospectus, no subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution
on such subsidiary&#146;s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)&nbsp;&nbsp;&nbsp;&nbsp;<U>PFIC</U>. The Company is not a Passive Foreign Investment Company
(&#147;<B>PFIC</B>&#148;) within the meaning of Section&nbsp;1296 of the United States Internal Revenue Code of 1966, and the Company is not likely to become a PFIC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss)&nbsp;&nbsp;&nbsp;&nbsp;<U>Forward-Looking Statements</U>. No
forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) contained in either the General Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt)&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing</U>. The Company is subject
to and in compliance in all material respects with the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act. The Common Stock is registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act and is listed on
the Exchange, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the Exchange, nor has the Company
received any notification that the Commission or FINRA is contemplating terminating such registration or listing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu)&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley Act</U>. There is and has been no failure on the part of the company or, to the
Company&#146;s knowledge, any of the Company&#146;s officers or directors, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith applicable to
the Company or such officers or directors as of the date hereof, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Unlawful Payments</U>. Neither the Company nor any of its subsidiaries nor any director,
officer, or employee thereof, or, to the Company&#146;s knowledge, any agent, affiliate or other person acting on behalf of the Company or any subsidiary, has (i)&nbsp;used any corporate funds for unlawful contributions, gifts, entertainment or
other unlawful expenses relating to political activity, (ii)&nbsp;made any direct or indirect unlawful payment to foreign or domestic government officials or employees, political parties or campaigns, political party officials, or candidates for
political office from corporate funds, (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any applicable anti-corruption laws, rules, or regulations of any other jurisdiction in
which the Company or any subsidiary conducts business, or (iv)&nbsp;made any other unlawful bribe, rebate, payoff, influence payment, kickback, or other unlawful payment to any person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww)&nbsp;&nbsp;&nbsp;&nbsp;<U>Loans</U>. There are no outstanding loans, advances (except normal advances for business
expenses in the ordinary course of business) or guarantees of indebtedness by the Company to or for the benefit of any of the officers or directors of the Company or any of their respective family members, except as disclosed in the Registration
Statement, the General Disclosure Package and the Prospectus or a document incorporated by reference therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;&nbsp;&nbsp;&nbsp;<U>Statistical and Market Data</U>. The statistical and market related data included or
incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate, and such data agree with the sources from which
they are derived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Anti-Money Laundering Laws</U>. The operations of the
Company and its subsidiaries are and have been conducted at all times in compliance with all applicable financial recordkeeping and reporting requirements, including those of the U.S. Bank Secrecy Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct
business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#147;<B>Anti-</B><B>Money Laundering Laws</B>&#148;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with OFAC Regulations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its subsidiaries, nor any director, officer or employee thereof, nor,
to the Company&#146;s knowledge, any agent, affiliate, representative or other person acting on behalf of the Company or any of its subsidiaries, is an individual or entity (&#147;<B>Person</B>&#148;) that is, or is owned or controlled by a Person
that is: (i)&nbsp;the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s Office of Foreign Assets Control (&#147;<B>OFAC</B>&#148;), the United Nations Security Council (&#147;<B>UNSC</B>&#148;), the European
Union (&#147;<B>EU</B>&#148;), Her Majesty&#146;s Treasury (&#147;<B>HMT</B>&#148;), or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), nor (ii)&nbsp;located, organized or resident in a country or territory that is
the subject of a U.S. government embargo (including, without limitation, Cuba, Iran, North Korea, Syria and the Crimea). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: (i)&nbsp;to fund or facilitate any activities or business of or with any Person that, at the time of such funding or facilitation, is the subject of
Sanctions, or in any country or territory that, at the time of such funding or facilitation, is the subject of a U.S. government embargo; or (ii)&nbsp;in any other manner that will result in a violation of Sanctions by any Person (including any
Person participating in the offering, whether as underwriter, advisor, investor or otherwise). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;For the past five (5)&nbsp;years, the Company and its subsidiaries have not knowingly engaged in,
are not now knowingly engaged in, and will not engage in, any direct or indirect dealings or transactions with any Person that at the time of the dealing or transaction is or was the subject of Sanctions or any country or territory that, at the time
of the dealing or transaction is or was the subject of a U.S. government embargo. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa)&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Associated Persons; FINRA Matters</U>. Neither the Company nor any of its affiliates (within the meaning of FINRA Rule 5121(f)(1)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated person (within
the meaning of Article I, Section&nbsp;1(ee) of the <FONT STYLE="white-space:nowrap">By-laws</FONT> of FINRA) of, any member firm of FINRA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Acquisitions or Dispositions</U>. Except as are described in the Registration Statement, the
General Disclosure Package and the Prospectus, there are no contracts, letters of intent, term sheets, agreement, arrangements or understandings with respect to the direct or indirect acquisition or disposition by the Company of material interests
in real or personal property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by or on behalf of the Company and delivered to the Representatives or to counsel
for the Underwriters shall be deemed to be a representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;P<SMALL>URCHASE</SMALL>, S<SMALL>ALE</SMALL> <SMALL>AND</SMALL> D<SMALL>ELIVERY</SMALL> <SMALL>OF</SMALL> O<SMALL>FFERED</SMALL>
S<SMALL>ECURITIES</SMALL>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to sell to the Underwriters, and the Underwriters agree,
severally and not jointly, to purchase from the Company the respective numbers of shares of Firm Stock set forth opposite the names of the Underwriters in <U>Schedule A</U> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price per share to be paid by the Underwriters to the Company for the Stock
will be $16.92 per share (the &#147;<B>Purchase Price</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will deliver the Firm Stock to the Representatives for the
respective accounts of the several Underwriters, through the facilities of The Depository Trust Company, issued in such names and in such denominations as the Representatives may direct by notice in writing to the Company given at or prior to 12:00
Noon, New York time, on the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) full business day preceding the Closing Date against payment of the aggregate Purchase Price therefor by wire transfer in federal (same day) funds to an
account at a bank specified by the Company payable to the order of the Company for the Firm Stock sold by them all at the offices of Cooley LLP, 4401 Eastgate Mall, San Diego, California 92121. Time shall be of the essence, and delivery at the time
and place specified pursuant to this Agreement is a further condition of the obligations of each Underwriter hereunder. The time and date of the delivery and closing shall be at 10:00 A.M., New York time, on August&nbsp;6, 2021, in accordance with
Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Exchange Act. The time and date of such payment and delivery are herein referred to as the &#147;<B>Closing Date</B>&#148;. The Closing Date and the location of delivery of, and the form of
payment for, the Firm Stock may be varied by agreement between the Company and the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may purchase all or
less than all of the Optional Stock. The price per share to be paid for the Optional Stock shall be the Purchase Price. The Company agrees to sell to the Underwriters the number of shares of Optional Stock specified in the written notice delivered
by the Representatives to the Company described below and the Underwriters agree, severally and not jointly, to purchase such shares of Optional Stock. Such shares of Optional Stock shall be purchased from the Company for the account of each
Underwriter in the same proportion as the number of shares of Firm Stock set forth opposite such Underwriter&#146;s name on <U>Schedule A</U> bears to the total number of shares of Firm Stock (subject to adjustment by the Representatives to
eliminate fractions). The option granted hereby may be exercised as to all or any part of the Optional Stock at any time, and from time to time, provided however, that notice of such exercise must be delivered not more than thirty (30)&nbsp;days
subsequent to the date of this Agreement. No Optional Stock shall be sold and delivered unless the Firm Stock previously has been, or simultaneously is, sold and delivered. The right to purchase the Optional Stock or any portion thereof may be
surrendered and terminated at any time upon notice by Representatives to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The option granted hereby shall be exercised by
written notice being given to the Company by the Representatives setting forth the number of shares of the Optional Stock to be purchased by the Underwriters and the date and time for delivery of and payment for the Optional Stock. Each date and
time for delivery of and payment for the Optional Stock (which may be the Closing Date, but not earlier) is herein called the &#147;<B>Option Closing Date</B>&#148; and shall in no event be earlier than two (2)&nbsp;business days (or one
(1)&nbsp;business day in the case notice is given prior to the initial Closing Date) nor later than five (5)&nbsp;business days after written notice is given. The Option Closing Date and the Closing Date are herein called the &#147;<B>Closing
Dates</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will deliver the Optional Stock to the Representatives for the respective accounts of the several
Underwriters in the case of the Company, through the facilities of The Depository Trust Company, issued in such names and in such denominations as the Representatives may direct by notice in writing to the Company given at or prior to 12:00 Noon,
New York time, on the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) full business day preceding the Option Closing Date against payment of the aggregate Purchase Price therefor by wire transfer in federal (same day) funds to an
account at a bank acceptable to the Representatives payable to the order of the Company, all at the offices of Cooley LLP, 4401 Eastgate Mall, San Diego, California 92121. Time shall be of the essence, and delivery at the time and place specified
pursuant to this Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is a further condition of the obligations of each Underwriter hereunder. The Option Closing Date and the location of delivery of, and the form of payment for, the Optional Stock may be varied by
agreement between the Company and the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The several Underwriters propose to offer the Stock for sale upon the terms and
conditions set forth in the Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;Further Agreements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;F<SMALL>URTHER</SMALL> A<SMALL>GREEMENTS</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> C<SMALL>OMPANY</SMALL>. The
Company agrees with the several Underwriters: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Required Filings; Amendments or Supplements;
Notice to the Representatives</U>. To prepare the Rule 462(b) Registration Statement, if necessary, in a form approved by the Representatives and file such Rule 462(b) Registration Statement with the Commission by 10:00 P.M., New York time, on the
date hereof, and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule 462(b) Registration Statement or give irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under the Rules and
Regulations; to prepare the Prospectus in a form approved by the Representatives containing information previously omitted at the time of effectiveness of the Registration Statement in reliance on Rules 430A of the Rules and Regulations and to file
such Prospectus pursuant to Rule 424(b) of the Rules and Regulations not later than the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) business day following the execution and delivery of this Agreement or, if applicable, such
earlier time as may be required by the Securities Act; to notify the Representatives immediately of the Company&#146;s intention to file or prepare any supplement or amendment to the Registration Statement or to the Prospectus and to make no
amendment or supplement to the Registration Statement, the General Disclosure Package or to the Prospectus to which the Representatives shall reasonably object by notice to the Company after a reasonable period to review; to advise the
Representatives, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective or any supplement to the General Disclosure Package or the Prospectus or any amended
Prospectus or any Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication has been filed and to furnish the Underwriters with copies thereof; to
file promptly all material required to be filed by the Company with the Commission pursuant to Rules 433(d) or 163(b)(2) of the Rules and Regulations, as the case may be; to file promptly all reports and any definitive proxy or information
statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus (or in lieu thereof,
the notice referred to in Rule 173(a) of the Rules and Regulations) is required in connection with the offering or sale of the Stock; to advise the Representatives, promptly after it receives notice thereof, of the issuance by the Commission of any
stop order or of any order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, of the suspension of the qualification of the Stock for offering or sale in any jurisdiction, of the initiation or, to the
Company&#146;s knowledge, threatening of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement, the General Disclosure Package or the Prospectus or for additional
information including, but not limited to, any request for information concerning any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; and, in the event of the issuance of any stop
order or of any order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus or suspending any such qualification, and promptly to use its best efforts to obtain the withdrawal of such
order. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Emerging Growth Company</U>. The Company will
promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (a)&nbsp;the completion of the distribution of the Firm Stock within the meaning of the Securities Act and
(b)&nbsp;completion of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined below). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If at any time following the distribution of any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication there occurred or occurs an event or development as a result of which such Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own
expense, such Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted Free Writing Prospectus</U>. The Company represents and agrees that, unless it obtains
the prior consent of the Representatives, and each Underwriter represents and agrees that, unless it obtains the prior consent of the Company and the Representatives, it has not made and will not make any offer relating to the Stock that would
constitute a &#147;free writing prospectus&#148; as defined in Rule 405 of the Rules and Regulations unless the prior written consent of the Representatives has been received (each, a &#147;<B>Permitted Free Writing Prospectus</B>&#148;); provided
that the prior written consent of the Representatives hereto shall be deemed to have been given in respect of the Issuer Free Writing Prospectuses included in <U>Schedule B</U> hereto. The Company represents that it has treated and agrees that it
will treat each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, comply with the requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Issuer Free Writing Prospectus, including the requirements
relating to timely filing with the Commission, legending and record keeping and will not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) of the Rules and
Regulations a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Ongoing Compliance</U>. If at any time prior to the date when a prospectus relating to the Stock
is required to be delivered (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) any event occurs or condition exists as a result of which the Prospectus as then amended or supplemented would include any untrue
statement of a material fact, or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made when the Prospectus is delivered (or in lieu thereof, the notice referred to in Rule
173(a) of the Rules and Regulations), not misleading, or if it is necessary at any time to amend or supplement the Registration Statement or the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus to
comply with the Securities Act or the Exchange Act, that the Company will promptly notify the Representatives thereof and upon their request will prepare an appropriate amendment or supplement or upon their request make an appropriate filing
pursuant to Section&nbsp;13 or 14 of the Exchange Act in form and substance satisfactory to the Representatives which will correct such statement or omission or effect such compliance and will use its reasonable best efforts to have any amendment to
the Registration Statement declared effective as soon as possible. The Company will furnish without charge to each Underwriter and to any dealer in securities as many copies as the Representatives may from time to time reasonably request of such
amendment or supplement. In case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations) relating to the Stock, the Company upon the request of the Representatives
will prepare promptly an amended or supplemented Prospectus as may be necessary to permit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
compliance with the requirements of Section&nbsp;10(a)(3) of the Securities Act and deliver to such Underwriter as many copies as such Underwriter may reasonably request of such amended or
supplemented Prospectus complying with Section&nbsp;10(a)(3) of the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment to General Disclosure Package</U>. If the General Disclosure Package is being used to
solicit offers to buy the Stock at a time when the Prospectus is not yet available to prospective purchasers and any event shall occur as a result of which, in the judgment of the Company or in the reasonable opinion of the Underwriters, it becomes
necessary to amend or supplement the General Disclosure Package in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, or to make the statements therein not conflict with the information contained
or incorporated by reference in the Registration Statement then on file and not superseded or modified, or if it is necessary at any time to amend or supplement the General Disclosure Package to comply with any law, the Company promptly will either
(i)&nbsp;prepare, file with the Commission (if required) and furnish to the Underwriters and any dealers an appropriate amendment or supplement to the General Disclosure Package or (ii)&nbsp;prepare and file with the Commission an appropriate filing
under the Exchange Act which shall be incorporated by reference in the General Disclosure Package so that the General Disclosure Package as so amended or supplemented will not, in the light of the circumstances then prevailing, be misleading or
conflict with the Registration Statement then on file, or so that the General Disclosure Package will comply with law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment to Issuer Free Writing Prospectus</U>. If at any time following issuance of an Issuer
Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or will conflict with the information contained in the Registration Statement, Pricing Prospectus or
Prospectus, including any document incorporated by reference therein and any prospectus supplement deemed to be a part thereof, and not superseded or modified or included or would include an untrue statement of a material fact or omitted or would
omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances prevailing at the subsequent time, not misleading, the Company has promptly notified or will promptly
notify the Representatives so that any use of the Issuer Free Writing Prospectus may cease until it is amended or supplemented and has promptly amended or will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to
eliminate or correct such conflict, untrue statement or omission. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to
the Company through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriter&#146;s Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery of Registration Statement</U>. To the extent not available on the Commission&#146;s
Electronic Data Gathering, Analysis and Retrieval system or any successor system (&#147;<B>EDGAR</B>&#148;), upon the request of the Representatives, to furnish promptly to the Representatives and to counsel for the Underwriters a signed copy of the
Registration Statement as originally filed with the Commission, and of each amendment thereto filed with the Commission, including all consents and exhibits filed therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery of Copies</U>. Upon request of the Representatives, to the extent not available on
EDGAR, to deliver promptly to the Representatives in New York City such number of the following documents as the Representatives shall reasonably request: (i)&nbsp;conformed copies of the Registration Statement as originally filed with the
Commission (in each case excluding exhibits), (ii) each Preliminary Prospectus, (iii)&nbsp;any Issuer Free Writing Prospectus, (iv)&nbsp;the Prospectus (the delivery of the documents referred to in clauses (i), (ii), (iii) and (iv)&nbsp;of this
paragraph (i)&nbsp;to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
made not later than 10:00 A.M., New York time, on the business day following the execution and delivery of this Agreement), (v) conformed copies of any amendment to the Registration Statement
(excluding exhibits), (vi) any amendment or supplement to the General Disclosure Package or the Prospectus (the delivery of the documents referred to in clauses (v)&nbsp;and (vi) of this paragraph (i)&nbsp;to be made not later than 10:00 A.M., New
York time, on the business day following the date of such amendment or supplement) and (vii)&nbsp;any document incorporated by reference in the General Disclosure Package or the Prospectus (excluding exhibits thereto) (the delivery of the documents
referred to in clause (vi)&nbsp;of this paragraph (h)&nbsp;to be made not later than 10:00 A.M., New York time, on the business day following the date of such document). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Earnings Statement</U>. To make generally available to its stockholders as soon as practicable,
but in any event not later than sixteen (16)&nbsp;months after the effective date of the Registration Statement (as defined in Rule 158(c) of the Rules and Regulations), an earnings statement of the Company and its subsidiaries (which need not be
audited) complying with Section&nbsp;11(a) of the Securities Act (including, at the option of the Company, Rule 158). However, so long as the Company is subject to the reporting requirements of either Section&nbsp;13 or Section&nbsp;15(d) of the
Exchange Act and is timely filing reports with the Commission on its EDGAR system, it is not required to furnish such annual reports or quarterly financial statements to its stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Blue Sky Compliance</U>. To take promptly from time to time such actions as the Representatives
may reasonably request to qualify the Stock for offering and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as the Representatives may reasonably designate and to continue such qualifications in effect, and to
comply with such laws, for so long as required to permit the offer and sale of Stock in such jurisdictions; provided that the Company and its subsidiaries shall not be obligated to (i)&nbsp;qualify as foreign corporations in any jurisdiction in
which they are not so qualified, (ii)&nbsp;file a general consent to service of process in any jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Reports</U>. Upon request, during the period of three (3)&nbsp;years from the date hereof, to
deliver to each of the Underwriters, (i)&nbsp;as soon as they are available, copies of all reports or other communications (financial or other) furnished to stockholders of the Company, and (ii)&nbsp;as soon as they are available, copies of any
reports and financial statements furnished or filed with the Commission or any national securities exchange on which the Stock is listed. However, so long as the Company is subject to the reporting requirements of either Section&nbsp;13 or
Section&nbsp;15(d) of the Exchange Act and is timely filing reports with the Commission on its EDGAR system, it is not required to furnish such reports or statements to the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT></U>. During the period commencing on and
including the date hereof and ending on and including the 90th day following the date of this Agreement, (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;) the Company will not, without the prior written consent of the
Representatives (which consent may be withheld at the sole discretion of the Representatives), directly or indirectly offer, sell (including, without limitation, any short sale), assign, transfer, pledge, contract to sell, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act, or otherwise dispose of, or announce the offering of, or submit or file any registration statement under the
Securities Act in respect of, any Common Stock, options, rights or warrants to acquire Common Stock or securities exchangeable or exercisable for or convertible into Common Stock (other than is contemplated by this Agreement with respect to the
Stock) or publicly announce any intention to do any of the foregoing; provided, however, that the Company may (i)&nbsp;issue Common Stock and options to purchase Common Stock, shares of Common Stock underlying options granted and other securities,
each pursuant to any director or employee stock option plan, stock ownership plan or dividend reinvestment plan of the Company in effect on the date hereof and described in the General </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Disclosure Package; (ii)&nbsp;file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register the offer and sale of securities to be issued
pursuant to existing equity incentive plans described in the Prospectus, and issue securities pursuant to such equity incentive plan (including, without limitation, the issuance of shares of Common Stock upon the exercise of options or other
securities issued pursuant to such equity incentive plan), provided that such equity incentive plan satisfies the transaction requirements of General Instruction A.1 of Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act, or
(iii)&nbsp;issue shares of Common Stock in connection with a licensing agreement, joint venture, acquisition or business combination or other collaboration or strategic transaction (including the filing of a registration statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> or other appropriate form with respect thereto), provided that the sum of the aggregate number of shares of Common Stock so issued shall not exceed 5% of the total outstanding shares of Common Stock outstanding
immediately following the completion of the transactions contemplated by this Agreement, provided further that clause (iii)&nbsp;shall not be available unless each recipient of shares of Common Stock, or securities exchangeable or exercisable for or
convertible into Common Stock, pursuant to clause (iii)&nbsp;shall be contractually prohibited from selling, offering, disposing of or otherwise transferring any such shares or securities during the remainder of the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. The Company will cause each officer and director of the Company to furnish to the Representative, prior to the Closing Date, a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT>
agreement, substantially in the form of <U>Exhibit I</U> hereto. In addition, the Company will direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such <FONT
STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery of SEC
Correspondence</U>. To supply the Underwriters with copies of all correspondence to and from, and all documents issued to and by, the Commission in connection with the registration of the Stock under the Securities Act or any of the Registration
Statement, any Preliminary Prospectus or the Prospectus, or any amendment or supplement thereto or document incorporated by reference therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Press Releases</U>. Prior to the Closing Date, not to issue any press release or other
communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business prospects (except for routine oral marketing communications in the
ordinary course of business and consistent with the past practices of the Company and of which the Representatives are notified), without the prior consent of the Representatives, unless in the judgment of the Company and its counsel, and after
notification to the Representatives, such press release or communication is required by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Regulation M</U>. Until the Underwriters shall have notified the Company of the
completion of the resale of the Stock, that the Company will not, and will use its reasonable best efforts to cause its affiliated purchasers (as defined in Regulation M under the Exchange Act) not to, either alone or with one or more other persons,
bid for or purchase, for any account in which it or any of its affiliated purchasers has a beneficial interest, any Stock, or attempt to induce any person to purchase any Stock; and not to, and to use its reasonable best efforts to cause its
affiliated purchasers not to, make bids or purchase for the purpose of creating actual, or apparent, active trading in or of raising the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<U>Registrar and Transfer Agent</U>. To maintain, at its expense, a registrar and transfer agent for
the Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<U>Use of Proceeds</U>. To apply the net proceeds from the sale of the Stock as set
forth in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds,&#148; and except as disclosed in the General Disclosure Package, the Company does not intend to use any of the proceeds
from the sale of the Stock hereunder to repay any outstanding debt owed to any affiliate of any Underwriter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing Fees</U>. To pay the required
Commission filing fees relating to the Stock within the time required by Rule 456(b)(1) of the Rules and Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) of the Rules and Regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange Listing</U>. To use its reasonable best efforts to list, subject to notice of issuance,
and to maintain the listing of the Stock on the Exchange. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;<U>Performance of Covenants and
Satisfaction of Conditions</U>. To use its reasonable best efforts to do and perform all things required to be done or performed under this Agreement by the Company prior to each Closing Date and to satisfy all conditions precedent to the delivery
of the Firm Stock and the Optional Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;P<SMALL>AYMENT</SMALL> <SMALL>OF</SMALL> E<SMALL>XPENSES</SMALL>. The Company agrees
to pay, or reimburse if paid by any Underwriter, whether or not the transactions contemplated hereby are consummated or this Agreement is terminated: (a)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the
Stock and any taxes payable in that connection; (b)&nbsp;the costs incident to the registration of the Stock under the Securities Act and the Exchange Act; (c)&nbsp;the costs incident to the preparation, printing and distribution of the Registration
Statement, the Base Prospectus, any Preliminary Prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus, any amendments, supplements and exhibits thereto or any document incorporated by reference therein and
the costs of printing, reproducing and distributing the &#147;Agreement Among Underwriters&#148; between the Representatives and the Underwriters, the Master Selected Dealers&#146; Agreement, the Underwriters&#146; Questionnaire, this Agreement and
any closing documents by mail, telex or other means of communications; (d)&nbsp;the fees and expenses (including related reasonable and documented fees and expenses of counsel for the Underwriters) incurred in connection with securing any required
review by FINRA of the terms of the sale of the Stock and any filings made with FINRA; (e)&nbsp;any applicable listing or other fees; (f)&nbsp;the fees and expenses (including reasonable and documented related fees and expenses of counsel to the
Underwriters) of qualifying the Stock under the securities laws of the several jurisdictions as provided in Section&nbsp;4(i)(k) and of preparing, printing and distributing wrappers, Blue Sky Memoranda and Legal Investment Surveys (provided, that,
the amount payable by the Company with respect to fees and disbursements of counsel to the Underwriters pursuant to subsections (d)&nbsp;and (f) shall not exceed $40,000 in the aggregate); (g) all fees and expenses of the registrar and transfer
agent of the Stock; (h)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Stock, including, without limitation, expenses
associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with
the prior approval of the Company, travel and lodging expenses of the officers of the Company and such consultants, and fifty percent (50%) of the cost of any aircraft chartered in connection with the road show with the prior consent of the Company,
and (i)&nbsp;all other costs and expenses incident to the offering of the Stock or the performance of the obligations of the Company under this Agreement (including, without limitation, the fees and expenses of the Company&#146;s counsel and the
Company&#146;s independent accountants); provided that, except to the extent otherwise provided in this Section&nbsp;5 and in Sections 9 and 10, the Underwriters shall pay their own costs and expenses, including the fees and expenses of their
counsel not contemplated herein, the travel and lodging expenses of the Underwriters, any transfer taxes on the resale of any Stock by them and the expenses of advertising any offering of the Stock made by the Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL> U<SMALL>NDERWRITERS</SMALL>&#146;
O<SMALL>BLIGATIONS</SMALL>. The respective obligations of the several Underwriters hereunder are subject to the accuracy, when made and as of the Applicable Time and on each Closing Date, of the representations and warranties of the Company
contained herein, to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder, and to each of the following additional terms and
conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Compliance; No Stop Orders</U>. The Registration Statement has
become effective under the Securities Act, and no stop order suspending the effectiveness of the Registration Statement or any part thereof, preventing or suspending the use of any Base Prospectus, any Preliminary Prospectus, the Prospectus or any
Permitted Free Writing Prospectus or any part thereof shall have been issued and no proceedings for that purpose or pursuant to Section&nbsp;8A under the Securities Act shall have been initiated or threatened by the Commission and no notice of
objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) of the Rules and Regulations shall have been received, and all requests for additional information on the part of
the Commission (to be included or incorporated by reference in the Registration Statement or the Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Representatives; the Rule 462(b) Registration Statement, if
any, each Issuer Free Writing Prospectus and the Prospectus shall have been filed with, the Commission within the applicable time period prescribed for such filing by, and in compliance with, the Rules and Regulations and in accordance with
Section&nbsp;4(i)(a), and the Rule 462(b) Registration Statement, if any, shall have become effective immediately upon its filing with the Commission; and FINRA shall have raised no unresolved objection to the fairness and reasonableness of the
terms of this Agreement or the transactions contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Material
Misstatements</U>. None of the Underwriters shall have discovered and disclosed to the Company on or prior to such Closing Date that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in
the opinion of counsel for the Underwriters, is material or omits to state any fact which, in the opinion of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading, or that the
General Disclosure Package, any Issuer Free Writing Prospectus or the Prospectus or any amendment or supplement thereto contains an untrue statement of fact which, in the opinion of such counsel, is material or omits to state any fact which, in the
opinion of such counsel, is material and is necessary in order to make the statements, in the light of the circumstances in which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate Proceedings</U>. All corporate proceedings and other legal matters incident to the
authorization, form and validity of each of this Agreement, the Stock, the Registration Statement, the General Disclosure Package, each Issuer Free Writing Prospectus and the Prospectus and all other legal matters relating to this Agreement and the
transactions contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the Underwriters, and the Company shall have furnished to such counsel all documents and information that they may reasonably request to enable
them to pass upon such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT>
Statement of Counsel for the Company</U>. Latham&nbsp;&amp; Watkins, LLP shall have furnished to the Representatives such counsel&#146;s written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement, as counsel to the Company,
addressed to the Underwriters and dated such Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Intellectual Property
Counsel for the Company.</U> Wilson Sonsini Goodrich&nbsp;&amp; Rosati P.C. shall have furnished to the Representatives such counsel&#146;s written opinion, as intellectual property counsel to the Company, addressed to the Underwriters and dated
such Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion and
<FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</U> The Representatives shall have received from Cooley LLP, counsel for the Underwriters, such opinion or opinions and
<FONT STYLE="white-space:nowrap">10b-5</FONT> Statement, dated such Closing Date, with respect to such matters as the Underwriters may reasonably require, and the Company shall have furnished to such counsel such documents as they request for
enabling them to pass upon such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Comfort Letter</U>. At the time of the execution of
this Agreement, the Representatives shall have received from BDO USA, LLP a letter, addressed to the Underwriters, executed and dated such date, in form and substance satisfactory to the Representatives (i)&nbsp;confirming that they are an
independent registered accounting firm with respect to the Company and its subsidiaries within the meaning of the Securities Act and the Rules and Regulations and PCAOB and (ii)&nbsp;stating the conclusions and findings of such firm, of the type
ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters, with respect to the financial statements and certain financial information contained or incorporated by reference in the Registration Statement, the General
Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Bring Down Comfort Letter</U>. On the effective date
of any post-effective amendment to the Registration Statement and on such Closing Date, the Representatives shall have received a letter (the &#147;<B>bring-down letter</B>&#148;) from BDO USA, LLP addressed to the Underwriters and dated such
Closing Date, confirming, as of the date of the bring-down letter (or, with respect to matters involving changes or developments since the respective dates as of which specified financial information is given in the General Disclosure Package and
the Prospectus, as the case may be, as of a date not more than three (3)&nbsp;business days prior to the date of the bring-down letter), the conclusions and findings of such firm, of the type ordinarily included in accountants&#146; &#147;comfort
letters&#148; to underwriters, with respect to the financial information and other matters covered by its letter delivered to the Representatives concurrently with the execution of this Agreement pursuant to paragraph (g)&nbsp;of this
Section&nbsp;6. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Officer</U><U>&#146;</U><U>s Certificate</U>. The Company shall have
furnished to the Representatives a certificate, dated such Closing Date, of its Chief Executive Officer and its Chief Financial Officer stating in their respective capacities as officers of the Company on behalf of the Company that (i)&nbsp;no stop
order suspending the effectiveness of the Registration Statement (including, for avoidance of doubt, any Rule 462(b) Registration Statement), or any post-effective amendment thereto, shall be in effect and no proceedings for such purpose shall have
been instituted or, to their knowledge, threatened by the Commission, (ii)&nbsp;for the period from and including the date of this Agreement through and including such Closing Date, there has not occurred any Material Adverse Effect, (iii)&nbsp;to
their knowledge, after reasonable investigation, as of such Closing Date, the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with all agreements and satisfied all conditions on its
part to be performed or satisfied hereunder at or prior to such Closing Date, and (iv)&nbsp;there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference in the General Disclosure
Package, any Material Adverse Effect in the financial position or results of operations of the Company, or any change or development that, singly or in the aggregate, would reasonably be expected to involve a Material Adverse Effect, except as set
forth in the General Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Material Adverse Effect</U>.
Since the date of the latest audited financial statements included in the General Disclosure Package or incorporated by reference in the General </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Disclosure Package as of the date hereof, (i)&nbsp;neither the Company nor any of its subsidiaries shall have sustained any loss or interference with its business from fire, explosion, flood or
other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth in the General Disclosure Package, and (ii)&nbsp;there shall not have been any change in the
capital stock or long-term debt of the Company or any of its subsidiaries, (other than as a result of the exercise of stock options or the award of stock options or restricted stock in the ordinary course of business pursuant to the Company&#146;s
equity plans that are described in the General Disclosure Package) or any change, or any development involving a prospective change, in or affecting the business, general affairs, management, financial position, stockholders&#146; equity or results
of operations of the Company and its subsidiaries, otherwise than as set forth in the General Disclosure Package, the effect of which, in any such case described in clause (i)&nbsp;or (ii) of this paragraph (j), is, in the judgment of the
Representatives, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or delivery of the Stock on the terms and in the manner contemplated in the General Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Legal Impediment to Issuance</U>. No action shall have been taken and no law, statute, rule,
regulation or order shall have been enacted, adopted or issued by any governmental or regulatory agency or body which would prevent the issuance or sale of the Stock; and no injunction, restraining order or order of any other nature by any federal
or state court of competent jurisdiction shall have been issued which would prevent the issuance or sale of the Stock or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Downgrade</U>. Subsequent to the execution and delivery of this Agreement (i)&nbsp;no
downgrading shall have occurred in the Company&#146;s corporate credit rating or the rating accorded the Company&#146;s debt securities by any &#147;nationally recognized statistical rating organization,&#148; as that term is defined by the
Commission for purposes of Rule 436(g)(2) of the Rules and Regulations and (ii)&nbsp;no such organization shall have publicly announced that it has under surveillance or review (other than an announcement with positive implications of a possible
upgrading), the Company&#146;s corporate credit rating or the rating of any of the Company&#146;s debt securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Market Conditions</U>. Subsequent to the execution and delivery of this Agreement there shall not
have occurred any of the following: (i)&nbsp;trading in any of the Company&#146;s securities shall have been suspended or materially limited by the Commission or the Exchange, or trading in securities generally on the New York Stock Exchange, Nasdaq
Global Select Market, Nasdaq Global Market, Nasdaq Capital Market or the NYSE MKT LLC or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, or trading in any securities of the Company on
any exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, shall have been suspended or materially limited, or minimum or maximum prices or maximum range for prices shall have been
established on any such exchange or such market by the Commission, by such exchange or market or by any other regulatory body or governmental authority having jurisdiction, (ii)&nbsp;a banking moratorium shall have been declared by Federal or state
authorities or a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States, (iii)&nbsp;the United States shall have become engaged in hostilities, or the subject of an act of
terrorism, or there shall have been an outbreak of or escalation in hostilities involving the United States, or there shall have been a declaration of a national emergency or war by the United States or (iv)&nbsp;there shall have occurred such a
material adverse change in general economic, political or financial conditions (or the effect of international conditions on the financial markets in the United States shall be such) as to make it, in the judgment of the Representatives,
impracticable or inadvisable to proceed with the sale or delivery of the Stock on the terms and in the manner contemplated in the General Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange Listing</U>. The Company shall have
filed a Notification: Listing of Additional shares with the Exchange and shall have received no objection thereto from the Exchange. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Good Standing</U>. The Representatives shall have received on and as of such Closing Date,
satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Representatives may reasonably request,
in each case in writing or any standard form of telecommunication from the appropriate Governmental Authorities of such jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U>. The Representatives shall have
received the written agreements, substantially in the form of <U>Exhibit</U><U></U><U>&nbsp;I</U> hereto, of the officers, directors and certain securityholders of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary&#146;s Certificate</U>. The Company shall have furnished to the Representatives a
Secretary&#146;s Certificate of the Company, in form and substance reasonably satisfactory to counsel for the Underwriters and customary for the type of offering contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<U>Chief Financial Officer Certificate</U>. On the date of this Agreement and on each Closing Date,
as the case may be, the Company shall have furnished to the Representatives a certificate, dated the respective dates of delivery thereof, of its Chief Financial Officer with respect to certain financial data contained in the General Disclosure
Package and the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Document</U>. On or prior to such Closing Date, the Company shall have furnished to
the Representatives such further certificates and documents as the Representatives may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters,
evidence and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;I<SMALL>NDEMNIFICATION</SMALL> <SMALL>AND</SMALL> C<SMALL>ONTRIBUTION</SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification of Underwriters by the Company</U>. The Company shall indemnify and hold harmless
each Underwriter, its affiliates, directors, officers, managers, members, employees, representatives and agents and each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of
the Exchange Act (collectively the &#147;<B>Underwriter Indemnified Parties</B>,&#148; and each an &#147;<B>Underwriter Indemnified Party</B>&#148;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or
proceeding in respect thereof), joint or several, to which such Underwriter Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding
arises out of or is based upon (A)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any
Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, the Registration Statement, the Prospectus, or in any amendment or
supplement thereto or document incorporated by reference therein or in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Common Stock, including any
roadshow or investor presentations made to investors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
by the Company (whether in person or electronically) (&#147;<B>Marketing Materials</B>&#148;), or (B)&nbsp;the omission or alleged omission to state in any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) of the Rules and
Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein, or in any Marketing Materials, a material fact required to be stated therein or necessary to make the
statements therein not misleading, and shall reimburse each Underwriter Indemnified Party promptly upon demand for any reasonable and documented legal fees or other expenses reasonably incurred by that Underwriter Indemnified Party in connection
with investigating, or preparing to defend, or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding,
as such fees and expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement or alleged
untrue statement in, or omission or alleged omission from any Preliminary Prospectus, the Registration Statement or the Prospectus, or any such amendment or supplement thereto, any Issuer Free Writing Prospectus or any Marketing Materials made in
reliance upon and in conformity with written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically for use therein, which information the parties hereto agree is limited to the
Underwriter&#146;s Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The indemnity agreement in this Section&nbsp;7(a) is not exclusive and is in addition to each other
liability which the Company might have under this Agreement or otherwise, and shall not limit any rights or remedies which may otherwise be available under this Agreement, at law or in equity to any Underwriter Indemnified Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification of Company by the Underwriters</U>. Each Underwriter, severally and not jointly,
shall indemnify and hold harmless the Company and its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of
the Exchange Act (collectively the &#147;<B>Company Indemnified Parties</B>&#148; and each a &#147;<B>Company Indemnified Party</B>&#148;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding
in respect thereof), joint or several, to which such Company Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or
is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule
433(d) of the Rules and Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement thereto, or (ii)&nbsp;the omission or alleged omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus,
any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement thereto, a material fact required to be stated
therein or necessary to make the statements therein not misleading, but in each case only to the extent that the untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written
information furnished to the Company through the Representatives by or on behalf of that Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriter&#146;s Information, and shall reimburse the
Company Indemnified Parties for any legal or other expenses reasonably incurred by such party in connection with investigating or preparing to defend or defending against or appearing as third party witness in connection with any such loss, claim,
damage, liability, action, investigation or proceeding, as such fees and expenses are incurred. This indemnity agreement is not exclusive and will be in addition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to any liability which the Underwriters might otherwise have and shall not limit any rights or remedies which may otherwise be available under this Agreement, at law or in equity to the Company
Indemnified Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Promptly after receipt by an indemnified party under this Section&nbsp;7
of notice of the commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this Section&nbsp;7, notify such indemnifying party in writing of the commencement of that
action; provided, however, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this Section&nbsp;7 except to the extent it has been materially prejudiced by such failure; and, provided,
further, that the failure to notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this Section&nbsp;7. If any such action shall be brought against an indemnified party,
and it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly notified indemnifying party, to assume the defense of such action
with counsel reasonably satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified party, be counsel to the indemnifying party). After notice from the indemnifying party to the indemnified
party of its election to assume the defense of such action, except as provided herein, the indemnifying party shall not be liable to the indemnified party under Section&nbsp;7 for any legal or other expenses subsequently incurred by the indemnified
party in connection with the defense of such action other than reasonable costs of investigation; provided, however, that any indemnified party shall have the right to employ separate counsel in any such action and to participate in the defense of
such action but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified party unless (i)&nbsp;the employment thereof has been specifically authorized in writing by the Company
in the case of a claim for indemnification under Section&nbsp;7(a) or the Representatives in the case of a claim for indemnification under Section&nbsp;7(b), (ii) such indemnified party shall have been advised by its counsel that there may be one or
more legal defenses available to it which are different from or additional to those available to the indemnifying party, or (iii)&nbsp;the indemnifying party has failed to assume the defense of such action and employ counsel reasonably satisfactory
to the indemnified party within a reasonable period of time after notice of the commencement of the action or the indemnifying party does not diligently defend the action after assumption of the defense, in which case, if such indemnified party
notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of (or, in the case of a failure to diligently
defend the action after assumption of the defense, to continue to defend) such action on behalf of such indemnified party and the indemnifying party shall be responsible for legal or other expenses subsequently incurred by such indemnified party in
connection with the defense of such action; provided, however, the indemnifying party shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general
allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of attorneys at any time for all such indemnified parties (in addition to any local counsel), which firm shall be designated in writing by
the Representatives if the indemnified parties under this Section&nbsp;7 consist of any Underwriter Indemnified Party or by the Company if the indemnified parties under this Section&nbsp;7 consist of any Company Indemnified Parties. Subject to this
Section&nbsp;7(c), the amount payable by an indemnifying party under Section&nbsp;7 shall include, but not be limited to, (x)&nbsp;reasonable legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or
preparing to defend or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any action, investigation, proceeding or claim, and (y)&nbsp;all amounts paid in settlement of any of the
foregoing. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of judgment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with respect to any pending or threatened action or any claim whatsoever, in respect of which indemnification or contribution could be sought under this Section&nbsp;7 (whether or not the
indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i)&nbsp;includes an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified party
from all liability arising out of such action or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the following
sentence, no indemnifying party shall be liable for settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled
with its written consent, if its consent has been unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against
any loss or liability by reason of such settlement or judgment. In addition, if at any time an indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel, such indemnifying
party agrees that it shall be liable for any settlement of the nature contemplated by Section&nbsp;7(a) effected without its written consent if (i)&nbsp;such settlement is entered into more than forty-five (45)&nbsp;days after receipt by such
indemnifying party of the request for reimbursement, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at least thirty (30)&nbsp;days prior to such settlement being entered into and (iii)&nbsp;such
indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;If the indemnification provided for in this Section&nbsp;7 is unavailable or insufficient to hold
harmless an indemnified party under Section&nbsp;7(a) or 7(b) then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid, payable or otherwise incurred by such indemnified party as a result of
such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof), as incurred, (i)&nbsp;in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand
and the Underwriters on the other from the offering of the Stock, or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;of this Section&nbsp;7(d) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause (i)&nbsp;of this Section&nbsp;7(d) but also the relative fault of the Company on the one hand and the Underwriters on the other with respect to the statements, omissions, acts or failures to act which resulted
in such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the
Underwriters on the other with respect to such offering shall be deemed to be in the same proportion as the total net proceeds from the offering of the Stock purchased under this Agreement (before deducting expenses) received by the Company bear to
the total underwriting discounts and commissions received by the Underwriters with respect to the Stock purchased under this Agreement, in each case as set forth in the table on the cover page of the Prospectus. The relative fault of the Company on
the one hand and the Underwriters on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to
information supplied by the Company on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission, act or failure
to act; provided that the parties hereto agree that the written information furnished to the Company through the Representatives by or on behalf of the Underwriters for use in the Preliminary Prospectus, the Registration Statement or the Prospectus,
or in any amendment or supplement thereto, consists solely of the Underwriter&#146;s Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company and the Underwriters agree that it
would not be just and equitable if contributions pursuant to Section&nbsp;7(d) above were to be determined by pro rata allocation or by any other method of allocation which does not take into account the equitable considerations referred to
Section&nbsp;7(d) above. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to in Section&nbsp;7(d) above shall be deemed to include, subject to
the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise
incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this Section&nbsp;7, no Underwriters shall be required to contribute any amount in excess of the
amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Stock exceeds the amount of any damages which the Underwriter has otherwise paid or become liable to pay by reason of
any untrue or alleged untrue statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute as provided in this Section&nbsp;7 are several in proportion to their respective underwriting
obligations and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;T<SMALL>ERMINATION</SMALL>. The obligations of the Underwriters hereunder may be terminated by the
Representatives, in their absolute discretion by notice given to the Company prior to delivery of and payment for the Firm Stock if, prior to that time, any of the events described in Sections 6(j), 6(l) or 6(m) have occurred or if the Underwriters
shall decline to purchase the Stock for any reason permitted under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;R<SMALL>EIMBURSEMENT</SMALL>
<SMALL>OF</SMALL> U<SMALL>NDERWRITERS</SMALL>&#146; E<SMALL>XPENSES</SMALL>. Notwithstanding anything to the contrary in this Agreement, if (a)&nbsp;this Agreement shall have been terminated pursuant to Section&nbsp;8 or 10, (b) the Company shall
fail to tender the Stock for delivery to the Underwriters for any reason not permitted under this Agreement, (c)&nbsp;the Underwriters shall decline to purchase the Stock for any reason permitted under this Agreement or (d)&nbsp;the sale of the
Stock is not consummated because any condition to the obligations of the Underwriters set forth herein is not satisfied or because of the refusal, inability or failure on the part of the Company to perform any agreement herein or to satisfy any
condition or to comply with the provisions hereof, then in addition to the payment of amounts in accordance with Section&nbsp;5, the Company shall reimburse the Underwriters for the reasonable and documented fees and expenses of Underwriters&#146;
counsel and for such other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses as shall have been reasonably incurred by them in connection with this Agreement and the proposed purchase of the
Stock, including, without limitation, travel and lodging expenses of the Underwriters, and upon demand the Company shall pay the full amount thereof to the Representatives; provided that if this Agreement is terminated pursuant to Section&nbsp;10 by
reason of the default of one or more Underwriters, the Company shall not be obligated to reimburse any defaulting Underwriter on account of expenses to the extent incurred by such defaulting Underwriter, <I>provided further</I> that the foregoing
shall not limit any reimbursement obligation of the Company to any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter under this Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>UBSTITUTION</SMALL> <SMALL>OF</SMALL> U<SMALL>NDERWRITERS</SMALL>. If any Underwriter or Underwriters shall default in its
or their obligations to purchase shares of Stock hereunder on any Closing Date and the aggregate number of shares which such defaulting Underwriter or Underwriters agreed but failed to purchase does not exceed ten percent (10%) of the total number
of shares to be purchased by all Underwriters on such Closing Date, the other Underwriters shall be obligated severally, in proportion to their respective commitments hereunder, to purchase the shares which such defaulting Underwriter or
Underwriters agreed but failed to purchase on such Closing Date. If any Underwriter or Underwriters shall so default and the aggregate number of shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to which such default or defaults occur is more than ten percent (10%) of the total number of shares to be purchased by all Underwriters on such Closing Date, and arrangements
satisfactory to the Representatives and the Company for the purchase of such shares by other persons are not made within <FONT STYLE="white-space:nowrap">forty-eight</FONT> (48)&nbsp;hours after such default, this Agreement shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the remaining Underwriters or substituted Underwriters are required hereby or agree to take up all or part of the shares of Stock of a
defaulting Underwriter or Underwriters on such Closing Date, as provided in this Section&nbsp;10, (i) the Company shall have the right to postpone such Closing Date, for a period of not more than five (5)&nbsp;full business days in order that the
Company may effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees promptly to file any amendments to the Registration Statement or
supplements to the Prospectus which may thereby be made necessary, and (ii)&nbsp;the respective numbers of shares to be purchased by the remaining Underwriters or substituted Underwriters shall be taken as the basis of their underwriting obligation
for all purposes of this Agreement. Nothing herein contained shall relieve any defaulting Underwriter of its liability to the Company or the other Underwriters for damages occasioned by its default hereunder. Any termination of this Agreement
pursuant to this Section&nbsp;10 shall be without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company, except that the representations, warranties, covenants, indemnities, agreements and
other statements set forth in Section&nbsp;2, the obligations with respect to expenses to be paid or reimbursed pursuant to Sections 5 and 9 and the provisions of Section&nbsp;7 and Sections 11 through 21, inclusive, shall not terminate and shall
remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;A<SMALL>BSENCE</SMALL> <SMALL>OF</SMALL> F<SMALL>IDUCIARY</SMALL>
R<SMALL>ELATIONSHIP</SMALL>. The Company acknowledges and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;each Underwriter&#146;s
responsibility to the Company is solely contractual in nature, the Representatives have been retained solely to act as underwriters in connection with the sale of the Stock and no fiduciary, advisory or agency relationship between the Company and
the Representatives has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether any of the Representatives has advised or is advising the Company on other matters; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the price of the Stock set forth in this Agreement was established by the Company following
discussions and arms-length negotiations with the Representatives, and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;it has been advised that the Representatives and their affiliates are engaged in a broad range of
transactions which may involve interests that differ from those of the Company and that the Representatives have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship;
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;it waives, to the fullest extent permitted by law, any claims it may have against the
Representatives for breach of fiduciary duty or alleged breach of fiduciary duty and agrees that the Representatives shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary duty claim or to any person
asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders, employees or creditors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>UCCESSORS</SMALL>; P<SMALL>ERSONS</SMALL> E<SMALL>NTITLED</SMALL> <SMALL>TO</SMALL> B<SMALL>ENEFIT</SMALL>
<SMALL>OF</SMALL> A<SMALL>GREEMENT</SMALL>. This Agreement shall inure to the benefit of and be binding upon the several Underwriters, the Company and their respective successors and assigns. Nothing expressed or mentioned in this Agreement is
intended or shall be construed to give any person, other than the persons mentioned in the preceding sentence, any legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions herein contained, this Agreement
and all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions and provisions hereof being intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person; except that the representations,
warranties, covenants, agreements and indemnities of the Company contained in this Agreement shall also be for the benefit of the Underwriter Indemnified Parties, and the indemnities of the several Underwriters shall be for the benefit of the
Company Indemnified Parties. It is understood that each Underwriter&#146;s responsibility to the Company is solely contractual in nature and the Underwriters do not owe the Company, or any other party, any fiduciary duty as a result of this
Agreement. No purchaser of any of the Stock from any Underwriter shall be deemed to be a successor or assign by reason merely of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>URVIVAL</SMALL> <SMALL>OF</SMALL> I<SMALL>NDEMNITIES</SMALL>, R<SMALL>EPRESENTATIONS</SMALL>, W<SMALL>ARRANTIES</SMALL>,
<SMALL>ETC</SMALL>. The respective indemnities, covenants, agreements, representations, warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by them respectively, pursuant to this
Agreement, shall remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter, the Company or any person controlling any of them and shall survive delivery of and payment for the Stock. Notwithstanding any
termination of this Agreement, including without limitation any termination pursuant to Section&nbsp;8 or Section&nbsp;10, the indemnities, covenants, agreements, representations, warranties and other statements forth in Sections 2, 5, 7 and 9 and
Sections 11 through 21, inclusive, of this Agreement shall not terminate and shall remain in full force and effect at all times. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;R<SMALL>ECOGNITION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> U.S. S<SMALL>PECIAL</SMALL> R<SMALL>ESOLUTION</SMALL>
R<SMALL>EGIMES</SMALL>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any Underwriter that is a Covered Entity becomes
subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective
under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such
Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could
be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;N<SMALL>OTICES</SMALL>. All statements, requests, notices and agreements hereunder shall be in writing, and: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;if to the Underwriters, shall be delivered or sent by mail, telex, facsimile transmission or email
to (i)&nbsp;Cowen and Company, LLC, 599 Lexington Avenue, New York, New York 10022, Attention: Head of Equity Capital Markets, Fax: <FONT STYLE="white-space:nowrap">(646)&nbsp;562-1249</FONT> with a copy to the General Counsel, Fax: (646) <FONT
STYLE="white-space:nowrap">562-1130,</FONT> (ii) SVB Leerink LLC, 1301 Avenue of the Americas, 12th Floor, New York, New York 10019, Attention: Stuart R. Nayman , (iii) Evercore Group L.L.C., 55 East 52nd Street, New York, New York 10055, Attention:
Kenneth A. Masotti, Esq. (fax: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-857-3101),</FONT></FONT> and (iv)&nbsp;Wells Fargo Securities, LLC, 500 West 33rd Street, New York, New York 10001, Attention of Equity Syndicate,
Fax: (212) <FONT STYLE="white-space:nowrap">214-5918;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;if to the Company shall be
delivered or sent by mail, telex, facsimile transmission or email to Avidity Biosciences, Inc., 10975 N. Torrey Pines Road, Suite 150, La Jolla, California, 92037 Attention: General Counsel; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that any notice to an Underwriter pursuant to Section&nbsp;7 shall be delivered or sent
by mail, or facsimile transmission to such Underwriter at its address set forth in its acceptance telex to the Representatives, which address will be supplied to any other party hereto by the Representatives upon request. Any such statements,
requests, notices or agreements shall take effect at the time of receipt thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;D<SMALL>EFINITION</SMALL> <SMALL>OF</SMALL>
C<SMALL>ERTAIN</SMALL> T<SMALL>ERMS</SMALL>. For purposes of this Agreement, (a) &#147;<B>affiliate</B>&#148; has the meaning set forth in Rule 405 under the Securities Act; (b) &#147;<B>business day</B>&#148; means any day on which the New York
Stock Exchange, Inc. is open for trading; (c) &#147;<B>subsidiary</B>&#148; has the meaning set forth in Rule&nbsp;405 of the Rules and Regulations; (d) &#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and
shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (e) &#147;Covered Entity&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 382.2(b); (f) &#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (g) &#147;U.S. Special Resolution Regime&#148;
means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<B>G<SMALL>OVERNING</SMALL> L<SMALL>AW</SMALL>, J<SMALL>URISDICTION</SMALL>, W<SMALL>AIVER</SMALL> <SMALL>OF</SMALL>
J<SMALL>URY</SMALL> T<SMALL>RIAL</SMALL>.</B><B> </B>This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including without limitation <FONT STYLE="white-space:nowrap">Section&nbsp;5-1401</FONT> of
the New York General Obligations. The Company irrevocably (a)&nbsp;submits to the exclusive jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of New York for the purpose of any suit, action or other proceeding
arising out of this Agreement or the transactions contemplated by this Agreement, the Registration Statement and any Preliminary Prospectus or the Prospectus, (b)&nbsp;agrees that all claims in respect of any such suit, action or proceeding may be
heard and determined by any such court, (c)&nbsp;waives to the fullest extent permitted by applicable law, any immunity from the jurisdiction of any such court or from any legal process, (d)&nbsp;agrees not to commence any such suit, action or
proceeding other than in such courts, and (e)&nbsp;waives, to the fullest extent permitted by applicable law, any claim that any such suit, action or proceeding is brought in an inconvenient forum. <B>Each of the parties to this Agreement hereby
waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;U<SMALL>NDERWRITERS</SMALL>&#146; I<SMALL>NFORMATION</SMALL>. The parties hereto acknowledge and agree that, for all purposes of
this Agreement, the Underwriters&#146; Information consists solely of the following information in the Prospectus: (i)&nbsp;the last paragraph on the front cover page concerning the terms of the offering by the Underwriters; and (ii)&nbsp;the
statements concerning the Underwriters contained in the eighth and tenth paragraphs under the heading &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;A<SMALL>UTHORITY</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> R<SMALL>EPRESENTATIVES</SMALL>. In connection with this Agreement,
the Representatives will act for and on behalf of the several Underwriters, and any action taken under this Agreement by the Representatives, will be binding on all the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;P<SMALL>ARTIAL</SMALL> U<SMALL>NENFORCEABILITY</SMALL>. The invalidity or unenforceability of any section, paragraph, clause or
provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph, clause or provision hereof. If any section, paragraph, clause or provision of this Agreement is for any reason determined to be invalid or
unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;G<SMALL>ENERAL</SMALL>. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior
written or oral and all contemporaneous oral agreements, understandings and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
negotiations with respect to the subject matter hereof. In this Agreement, the masculine, feminine and neuter genders and the singular and the plural include one another. The section headings in
this Agreement are for the convenience of the parties only and will not affect the construction or interpretation of this Agreement. This Agreement may be amended or modified, and the observance of any term of this Agreement may be waived, only by a
writing signed by the Company and the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22.&nbsp;&nbsp;&nbsp;&nbsp;C<SMALL>OUNTERPARTS</SMALL>. This Agreement may be signed in any number
of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may be delivered via facsimilie, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective
for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding please indicate your acceptance of
this Agreement by signing in the space provided for that purpose below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AVIDITY BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sarah Boyce</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sarah Boyce</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Underwriting Agreement]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted as of the date first above written:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COWEN AND COMPANY, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SVB LEERINK LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EVERCORE GROUP L.L.C.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WELLS FARGO SECURITIES, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acting on their own behalf</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">and as Representatives of several Underwriters</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">listed on Schedule A to this Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COWEN AND COMPANY, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tanya Joseph</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tanya Joseph</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SVB LEERINK LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dan Dubin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dan Dubin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice Chairman and Global <FONT STYLE="white-space:nowrap">Co-Head</FONT> of Investment Banking</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EVERCORE GROUP L.L.C</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maren Winnick</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Maren Winnick</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WELLS FARGO SECURITIES, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Bohn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Bohn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Underwriting Agreement]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares&nbsp;of&nbsp;Firm<BR>Stock to be Purchased</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares&nbsp;of<br>Optional Stock to be<BR>Purchased</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,560,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,560,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,080,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">312,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Use Free Writing Prospectuses </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pricing Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Firm Stock to be
Sold: 8,000,000 shares </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering Price: $18.00 per share </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriting Discounts and Commissions: 6.00% </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated Net
Proceeds to the Company (after underwriting discounts and commissions, but before transaction expenses): $135,360,000.00 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C<SMALL>OWEN</SMALL> <SMALL>AND</SMALL> C<SMALL>OMPANY</SMALL>, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB L<SMALL>EERINK</SMALL> LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E<SMALL>VERCORE</SMALL>
G<SMALL>ROUP</SMALL> L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">W<SMALL>ELLS</SMALL> F<SMALL>ARGO</SMALL> S<SMALL>ECURITIES</SMALL>, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cowen and Company, LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10022 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SVB Leerink LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">53 State Street, 40th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evercore Group L.L.C. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">55 East 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wells Fargo Securities, LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">500 West 33rd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10001 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Avidity Biosciences, Inc. &#150; Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for
Shares of Common Stock </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs and Madams: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement (this &#147;<B>Agreement</B>&#148;) is being delivered to you in connection with the proposed Underwriting Agreement (the
&#147;<B>Underwriting Agreement</B>&#148;) between Avidity Biosciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;) and Cowen and Company, LLC, SVB Leerink LLC, Evercore Group L.L.C. and Wells Fargo Securities, LLC, as
representatives (the &#147;<B>Representatives</B>&#148;) of a group of underwriters (collectively, the &#147;<B>Underwriters</B>&#148;), to be named therein, and the other parties thereto (if any), relating to the proposed public offering (the
&#147;<B>Offering</B>&#148;) of shares of the common stock, par value $0.0001 per share (the &#147;<B>Common Stock</B>&#148;) of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to
induce the Underwriters to enter into the Underwriting Agreement, and in light of the benefits that the Offering of the Common Stock will confer upon the undersigned in his, her or its capacity as a securityholder and/or an officer, director or
employee of the Company, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each Underwriter that, during the period beginning on the date hereof through and including
the date that is the 90th day after the date of the Underwriting Agreement (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;), the undersigned will not, and will not cause or direct any of its affiliates to, without the
prior written consent of the Representatives, directly or indirectly, (i)&nbsp;offer, sell, assign, transfer, pledge, contract to sell, or otherwise </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dispose of, or announce the intention to otherwise dispose of, any shares of Common Stock (including, without limitation, Common Stock which may be deemed to be beneficially owned by the
undersigned in accordance with the rules and regulations promulgated under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;) as the same may be amended or supplemented from time to time (such shares, the
&#147;<B>Beneficially Owned Shares</B>&#148;)) or securities convertible into or exercisable or exchangeable for Common Stock, (ii)&nbsp;enter, or announce the intention to enter, into any swap, hedge or similar agreement or arrangement that
transfers, is designed to transfer or reasonably could be expected to transfer (whether by the undersigned or someone other than the undersigned) in whole or in part the economic risk of ownership of the Beneficially Owned Shares or securities
convertible into or exercisable or exchangeable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (the &#147;<B>Prohibited
Activity</B>&#148;), or (iii)&nbsp;engage in, or announce the intention to engage in, any short selling of the Common Stock or securities convertible into or exercisable or exchangeable for Common Stock. The undersigned represents and warrants that
the undersigned is not, and has not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement that is designed to or which reasonably could be expected to lead to or result in any Prohibited Activity
during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions set forth in the second paragraph shall not apply to:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;if (i)&nbsp;the undersigned is a natural person, any transfers made by the undersigned (a)&nbsp;as a bona fide
gift or gifts to any member of the immediate family (as defined below) of the undersigned, (b)&nbsp;by will or intestate succession upon the death of the undersigned or (c)&nbsp;to a trust the beneficiaries of which are exclusively the undersigned
or members of the undersigned&#146;s immediate family (as defined below) , or (ii)&nbsp;if the undersigned is a trust, to a trustor, trustee (or <FONT STYLE="white-space:nowrap">co-trustee)</FONT> or beneficiary of the trust or to the estate of the
beneficiary of such trust; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;if the undersigned is a corporation, partnership, limited liability company or other
business entity, any transfers to any stockholder, partner or member of, or owner of a similar equity interest in, the undersigned, as the case may be, if, in any such case, such transfer is not for value; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer
made by the undersigned (a)&nbsp;in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&#146;s capital stock, partnership interests, membership interests or other similar equity
interests, as the case may be, or all or substantially all of the undersigned&#146;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this Agreement or (b)&nbsp;to another corporation, partnership,
limited liability company or other business entity so long as the transferee is an affiliate (as defined below) of the undersigned and such transfer is not for value; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;transactions relating to Common Stock or other securities convertible into or exercisable or exchangeable for Common
Stock acquired in open market transactions after completion of the Offering, <I>provided</I> that no such transaction is required to be, or is, publicly announced (whether on Form 4, Form 5 or otherwise) during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(5)&nbsp;&nbsp;&nbsp;&nbsp;the entry, by the undersigned, at any time on or after
the date of the Underwriting Agreement, of any trading plan providing for the sale of Common Stock by the undersigned, which trading plan meets the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1(c)</FONT> under the Exchange Act,
<I>provided</I>, <I>however</I>, that such plan does not provide for, or permit, the sale of any Common Stock during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and no public announcement or filing is voluntarily made or required
regarding such plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(6)&nbsp;&nbsp;&nbsp;&nbsp;any transfers made by the undersigned to the Company to satisfy
tax withholding obligations pursuant to the Company&#146;s equity incentive plans or arrangements disclosed in the Prospectus (as defined in the Underwriting Agreement); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(7)&nbsp;&nbsp;&nbsp;&nbsp;any transfers pursuant to a court or regulatory agency order, a qualified domestic order or in connection with a
divorce settlement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(8)&nbsp;&nbsp;&nbsp;&nbsp;any transfers to the Company pursuant to any contractual arrangement in effect on the date
of the Prospectus that provides for the repurchase by the Company or forfeiture of the undersigned&#146;s Common Stock or other securities convertible into or exercisable or exchangeable for Common Stock in connection with the termination of the
undersigned&#146;s service to the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(9)&nbsp;&nbsp;&nbsp;&nbsp;any transfers upon the completion of a bona fide third-party tender
offer, merger, consolidation or other similar transaction, approved by the Company&#146;s Board of Directors, made to all holders of the Company&#146;s securities involving a change of control of the Company, <I>provided </I>that, in the event that
such tender offer, merger, consolidation or other similar transaction is not completed, any Common Stock or securities convertible into or exercisable or exchangeable for Common Stock held by the undersigned shall remain subject to the restrictions
on transfer set forth in this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement (for purposes hereof, &#147;change of control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one
transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities
of the Company (or the surviving entity)); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that (A)&nbsp;in the case of any transfer described in clause (1), (2),
(3) or (7)&nbsp;above, it shall be a condition to the transfer that the transferee executes and delivers to the Representatives, acting on behalf of the Underwriters, not later than one business day prior to such transfer, a written agreement, in
substantially the form of this Agreement (it being understood that any references to &#147;immediate family&#148; in the agreement executed by such transferee shall expressly refer only to the immediate family of the undersigned and not to the
immediate family of the transferee) and otherwise satisfactory in form and substance to the Representatives, and (B)&nbsp;in the case of any transfer described in clause (1), (2), (3), (4), (6), (7) or (8)&nbsp;above, no public announcement or
filing is voluntarily made regarding such transfer during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and if the undersigned is required to file a report under Section&nbsp;16(a) of the Exchange Act, reporting a reduction in
beneficial ownership of shares of Common Stock or Beneficially Owned Shares or any securities convertible into or exercisable or exchangeable for Common Stock or Beneficially Owned Shares during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Period, the undersigned shall include a statement in such report to the effect that, (i)&nbsp;in the case of any transfer pursuant to clause (1)&nbsp;above, such transfer is being made as a gift or by will or intestate succession, (ii)&nbsp;in the
case of any transfer pursuant to clause (2)&nbsp;above, such transfer is being made to a stockholder, partner or member of, or owner of a similar equity interest in, the undersigned and is not a transfer for value, (iii)&nbsp;in the case of any
transfer pursuant to clause (3)&nbsp;above, such transfer is being made either (a)&nbsp;in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&#146;s capital stock, partnership
interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the undersigned&#146;s assets or (b)&nbsp;to another corporation, partnership, limited liability company or other business entity
that is an affiliate of the undersigned and such transfer is not for value, (iv)&nbsp;in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case of any transfer pursuant to clause (6)&nbsp;above, such transfer is being made to satisfy tax withholding obligations, (v)&nbsp;in the case of any transfer pursuant to clause (7)&nbsp;above,
such transfer is being made pursuant to a court or regulatory agency order, a qualified domestic order or in connection with a divorce settlement, (vi)&nbsp;in the case of any transfer pursuant to clause (8)&nbsp;above, such transfer is being made
in connection with the termination of the undersigned&#146;s employment or other services and (vii)&nbsp;in the case of any transfer pursuant to clause (1), (2), (3) or (7)&nbsp;above, that the shares remain subject to the terms of this Agreement.
For purposes of this paragraph, &#147;immediate family&#148; shall mean a spouse, domestic partner, child, grandchild or other lineal descendant (including by adoption), father, mother, brother or sister of the undersigned; and &#147;affiliate&#148;
shall have the meaning set forth in Rule 405 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For avoidance of doubt, nothing in this Agreement prohibits the undersigned from
exercising any options or warrants to purchase Common Stock (which exercises may be effected on a cashless basis to the extent the instruments representing such options or warrants permit exercises on a cashless basis), it being understood that any
Common Stock issued upon such exercises will be subject to the restrictions of this Agreement and <I>provided</I>, <I>however</I>, that no public announcement or filing is voluntarily made regarding such exercise during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period and provided that if the undersigned is required to file a report under Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership of such options or warrants during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, the undersigned shall include a statement in such report to the effect that the disposition relates to the exercise of an option or warrant, as applicable, and that the shares of Common Stock
received upon exercise are subject to the restrictions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to enable this covenant to be enforced, the undersigned hereby
consents to the placing of legends or stop transfer instructions with the Company&#146;s transfer agent with respect to any Common Stock or securities convertible into or exercisable or exchangeable for Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned further agrees that it will not, during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, make any demand or request
for or exercise any right with respect to the registration under the Securities Act, of any shares of Common Stock or other Beneficially Owned Shares or any securities convertible into or exercisable or exchangeable for Common Stock or other
Beneficially Owned Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into
this Agreement and that this Agreement has been duly authorized (if the undersigned is not a natural person), executed and delivered by the undersigned and is a valid and binding agreement of the undersigned. This Agreement and all authority herein
conferred are irrevocable and shall survive the death or incapacity of the undersigned (if a natural person) and shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be
performed in such state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have
the Underwriters solicited any action from the undersigned with respect to the Offering of the shares of Common Stock and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed
appropriate. The undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Offering, the
Representatives and the other Underwriters are not making a recommendation to you to enter into this&nbsp;Agreement and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a
recommendation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby consents to receipt of this&nbsp;Agreement in electronic form and understands and
agrees that this&nbsp;Agreement may be signed electronically. In the event that any signature is delivered by facsimile transmission, electronic mail, or otherwise by electronic transmission evidencing an intent to sign this&nbsp;Agreement, such
facsimile transmission, electronic mail or other electronic transmission shall create a valid and binding obligation of the undersigned with the same force and effect as if such signature were an original. Execution and delivery of
this&nbsp;Agreement by facsimile transmission, electronic mail or other electronic transmission is legal, valid and binding for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If (i)&nbsp;the Company notifies the Representatives in writing that it does not intend to proceed with the Offering, (ii)&nbsp;the
Underwriting Agreement is not executed by September&nbsp;30, 2021, or (iii)&nbsp;the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated for any reason prior to payment for and
delivery of any Common Stock to be sold thereunder, then this Agreement shall immediately be terminated and the undersigned shall automatically be released from all of his, her or its obligations under this Agreement. The undersigned acknowledges
and agrees that whether or not any public offering of Common Stock actually occurs depends on a number of factors, including market conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Name of Securityholder - Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Name of Signatory if Securityholder is an entity - Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Title of Signatory if Securityholder is an entity - Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d171991dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="4">


<IMG SRC="g171991dsp01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">12670 High Bluff Drive</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">San Diego, California 92130</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Tel: +1.858.523.5400 Fax: +1.858.523.5450</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">www.lw.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Beijing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Moscow</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Munich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Century&nbsp;City</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Orange County</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">August&nbsp;4, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chicago</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dubai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Riyadh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">D&uuml;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seoul</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shanghai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Houston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silicon Valley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Los Angeles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tokyo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Madrid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Washington, D.C.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Milan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10975
N. Torrey Pines Road, Suite 150 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Jolla, California 92037 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
<FONT STYLE="white-space:nowrap">(333-257691);</FONT> 9,200,000 shares of Common Stock, par value 0.0001 per share</U> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have acted as special counsel to Avidity Biosciences, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;),
in connection with the offering of up to 9,200,000 shares (including up to 1,200,000 shares issuable upon exercise of the underwriters&#146; option to purchase additional shares) of common stock of the Company, par value $0.0001 per share (the
&#147;<B><I>Shares</I></B>&#148;). The offering of the Shares was made under<B><I> </I></B>a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;),
filed with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) on July&nbsp;2, 2021 (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-257691)</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;), a
base prospectus dated July&nbsp;2, 2021 included in the Registration Statement at the time it originally became effective (the &#147;<B><I>Base Prospectus</I></B>&#148;), a preliminary prospectus supplement dated August&nbsp;2, 2021 filed with the
Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the &#147;<B><I>Preliminary Prospectus</I></B>&#148;), and a prospectus supplement dated August&nbsp;3, 2021 filed with the Commission pursuant to Rule 424(b) under
the Act (together with the Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;). The Shares are being sold pursuant to an underwriting agreement dated August&nbsp;3, 2021 by and among the Company and Cowen and Company, LLC, SVB Leerink LLC,
Evercore Group L.L.C. and Wells Fargo Securities, LLC, as representatives of the several underwriters listed on Schedule A thereto (the &#147;<B><I>Underwriting Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, the Preliminary Prospectus or the Prospectus, other than as expressly stated
herein with respect to the issue of the Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>August 4, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g171991g0804234506330.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such matters of fact and questions of law as we have
considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We
are opining herein as to the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), and we express no opinion with respect to any other laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have
been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by
the Underwriting Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we
have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company&#146;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated August&nbsp;4, 2021 and to the reference to our firm in the
Prospectus under the heading &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Latham&nbsp;&amp; Watkins LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d171991dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g171991g0804134933182.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LA JOLLA, Calif., August&nbsp;2, 2021 /PRNewswire/ &#150; Avidity Biosciences, Inc. (Nasdaq: RNA),&nbsp;a biopharmaceutical company committed to delivering a
new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>), today announced that it intends to offer and sell, subject to market and other conditions, $100&nbsp;million
of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 15% of the shares of common stock
offered in the public offering. All of the shares to be sold in the offering are to be sold by Avidity. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities: to complete its Phase
1/2 MARINA trial for AOC 1001; to advance AOC 1044 and its AOC FSHD program into clinical development; to further advance its AOC platform in and beyond its muscle franchise; and towards working capital and other general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen, SVB Leerink, Evercore ISI and Wells Fargo Securities are acting as joint bookrunning managers for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are being offered by Avidity pursuant to a shelf registration statement that became automatically effective upon filing with
the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from: Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by
telephone at (833) <FONT STYLE="white-space:nowrap">297-2926;</FONT> from SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) <FONT STYLE="white-space:nowrap">808-7525,</FONT>
ext. 6105, or by email at syndicate@svbleerink.com; from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) <FONT STYLE="white-space:nowrap">474-0200,</FONT> or
by email at ecm.prospectus@evercore.com; or from Wells Fargo </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, NY 10001, or by telephone at (800) <FONT STYLE="white-space:nowrap">326-5897,</FONT> or by email at
cmclientsupport@wellsfargo.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Avidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity Biosciences, Inc.&#146;s mission
is to profoundly improve people&#146;s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>). Avidity&#146;s proprietary AOCs are designed to combine
the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity&#146;s lead product candidate, AOC 1001, is designed to treat
myotonic dystrophy type 1 (DM1). The FDA has cleared Avidity to proceed with the Phase 1/2 MARINA<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). Its advancing and expanding
pipeline also includes programs in facioscapulohumeral muscular dystrophy (FSHD), Duchenne Muscular Dystrophy (DMD), muscle atrophy and Pompe disease. The company is planning for AOC 1044, the lead of three programs for the treatment of DMD, and its
AOC FSHD program to enter the clinic in 2022. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is
headquartered in La Jolla, CA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These
statements are based on the company&#146;s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding Avidity&#146;s expectations of the completion, timing and size of the proposed public
offering and the anticipated use of proceeds therefrom. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of its plans will be achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Avidity&#146;s business,
including those described in the company&#146;s prior press releases and the company&#146;s filings with the Securities and Exchange Commission (SEC), including under the heading &#147;Risk Factors&#148; in the company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Avidity undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACTS: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathleen Gallagher </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858)
<FONT STYLE="white-space:nowrap">401-7900</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>kath.gallagher@aviditybio.com</U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amy Conrad </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Juniper Point </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">366-3243</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>amy@juniper-point.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>d171991dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g171991g0804134933182.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LA JOLLA, Calif., August&nbsp;3, 2021 /PRNewswire/ &#150; Avidity Biosciences, Inc. (Nasdaq: RNA),&nbsp;a biopharmaceutical company committed to delivering a
new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>), today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a
price to the public of $18.00 per share. All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering
expenses, are expected to be $144.0&nbsp;million. The offering is expected to close on or about August&nbsp;6, 2021, subject to the satisfaction of customary closing conditions. In addition, Avidity has granted the underwriters a <FONT
STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 1,200,000 shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity intends to use the net proceeds
from this offering, together with its existing cash, cash equivalents and marketable securities: to complete its Phase 1/2 MARINA trial for AOC 1001; to advance AOC 1044 and its AOC FSHD program into clinical development; to further advance its AOC
platform in and beyond its muscle franchise; and towards working capital and other general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen, SVB Leerink, Evercore ISI and Wells
Fargo Securities are acting as joint bookrunning managers for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are being offered by Avidity pursuant to a
shelf registration statement that became automatically effective upon filing with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus relating to this offering were filed with the SEC and a
final prospectus supplement relating to the offering will be filed with the SEC. The offering may be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the
accompanying prospectus relating to this offering may be obtained from: Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833) <FONT STYLE="white-space:nowrap">297-2926;</FONT> from SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) <FONT
STYLE="white-space:nowrap">808-7525,</FONT> ext. 6105, or by email at syndicate@svbleerink.com; from Evercore Group L.L.C., </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) <FONT STYLE="white-space:nowrap">474-0200,</FONT> or by email at
ecm.prospectus@evercore.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, NY 10001, or by telephone at (800) <FONT STYLE="white-space:nowrap">326-5897,</FONT> or by email at
cmclientsupport@wellsfargo.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Avidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity Biosciences, Inc.&#146;s mission
is to profoundly improve people&#146;s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>). Avidity&#146;s proprietary AOCs are designed to combine
the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity&#146;s lead product candidate, AOC 1001, is designed to treat
myotonic dystrophy type 1 (DM1). The FDA has cleared Avidity to proceed with the Phase 1/2 MARINA<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). Its advancing and expanding
pipeline also includes programs in facioscapulohumeral muscular dystrophy (FSHD), Duchenne Muscular Dystrophy (DMD), muscle atrophy and Pompe disease. The company is planning for AOC 1044, the lead of three programs for the treatment of DMD, and its
AOC FSHD program to enter the clinic in 2022. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is
headquartered in La Jolla, CA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Avidity cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These
statements are based on the company&#146;s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding Avidity&#146;s expectations of market conditions and the satisfaction of customary
closing conditions related to the public offering, the expected closing of the offering and the anticipated use of proceeds therefrom. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of its
plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public
offering, as well as risks and uncertainties inherent in Avidity&#146;s business, including those described in the company&#146;s prior press releases and the company&#146;s filings with the Securities and Exchange Commission (SEC), including under
the heading &#147;Risk Factors&#148; in the company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent filings with </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Avidity undertakes no obligation to update such statements
to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACTS: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathleen
Gallagher </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">401-7900</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>kath.gallagher@aviditybio.com</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amy Conrad </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Juniper Point </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858)
<FONT STYLE="white-space:nowrap">366-3243</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>amy@juniper-point.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>rna-20210803.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 8/4/2021 11:15:59 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:rna="http://www.aviditybiosciences.com/20210803"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.aviditybiosciences.com/20210803"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rna-20210803_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rna-20210803_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>rna-20210803_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 8/4/2021 11:15:59 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>rna-20210803_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 8/4/2021 11:15:59 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rna-20210803.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g171991dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g171991dsp01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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5\5O GW8XD"*/H!Q0!-0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g171991g0804134933182.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g171991g0804134933182.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "2 08# 2(  A$! Q$!_\0
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M"%-.LKB><C"^8 HS^!)-0>%_#NIZOKO_  DFOJR,#OAB<8)/8X[*.PI@=[>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O-OB\?]"TK_ *ZR?R%>DUC:SX>M];O]-FN\-!9NTAB(XD8@8S[#&:VH35.H
MI/H<V+I2K494X[O_ #.1^'?@W[,D>MZC%^_89MHF'W ?XR/4]O05Z/2#I2U-
M6K*K+FD5AZ$*%-0@%%%%9FX4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g171991g0804234506330.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g171991g0804234506330.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  , *(# 2(  A$! Q$!_\0
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>XX65UA\,13Q!B$E+>7O7LVTOE<]<'D45W=% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>d171991d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rna-20210803.xsd" xlink:type="simple"/>
    <context id="duration_2021-08-03_to_2021-08-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599901</identifier>
        </entity>
        <period>
            <startDate>2021-08-03</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-08-03_to_2021-08-03">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-08-03_to_2021-08-03"
      id="Hidden_dei_EntityCentralIndexKey">0001599901</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-08-03_to_2021-08-03">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-08-03_to_2021-08-03">2021-08-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-08-03_to_2021-08-03">AVIDITY BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-08-03_to_2021-08-03">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-08-03_to_2021-08-03">001-39321</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-08-03_to_2021-08-03">46-1336960</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-08-03_to_2021-08-03">10975 N. Torrey Pines Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-08-03_to_2021-08-03">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-08-03_to_2021-08-03">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-08-03_to_2021-08-03">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-08-03_to_2021-08-03">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-08-03_to_2021-08-03">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-08-03_to_2021-08-03">401-7900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-08-03_to_2021-08-03">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-08-03_to_2021-08-03">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-08-03_to_2021-08-03">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-08-03_to_2021-08-03">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-08-03_to_2021-08-03">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-08-03_to_2021-08-03">RNA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-08-03_to_2021-08-03">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-08-03_to_2021-08-03">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2021-08-03_to_2021-08-03">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140592968611480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001599901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  03,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AVIDITY BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1336960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10975 N. Torrey Pines Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-7900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ U($$4Y>*NQS
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M"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ U($$4P=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #4@013
MG2"Y<>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #4@013F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -2!!%.!?FI.<P0
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M2P$"% ,4    " #4@013)!Z;HJT   #X 0  &@              @ 'G$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #4@01399!Y
MDAD!  #/ P  $P              @ ',$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"   6%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d171991d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d171991d8k.htm">d171991d8k.htm</File>
    <File>d171991dex11.htm</File>
    <File>d171991dex51.htm</File>
    <File>d171991dex991.htm</File>
    <File>d171991dex992.htm</File>
    <File>rna-20210803.xsd</File>
    <File>rna-20210803_lab.xml</File>
    <File>rna-20210803_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d171991d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d171991d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rna-20210803_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rna-20210803_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "rna-20210803.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rna",
   "nsuri": "http://www.aviditybiosciences.com/20210803",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d171991d8k.htm",
      "contextRef": "duration_2021-08-03_to_2021-08-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d171991d8k.htm",
      "contextRef": "duration_2021-08-03_to_2021-08-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aviditybiosciences.com//20210803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-21-236306-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-236306-xbrl.zip
M4$L#!!0    ( -2!!%-ZF9SU2A0  (%\   .    9#$W,3DY,60X:RYH=&WM
M/6USXCC2WZ_J_H.*?:ED*[P8DDP@F5QE&&:/VTR2"MG;O>?+EK!%T,587LD.
M<+_^Z99D8_,62 C,S&9J=P8CJ=7J]VY)YNP?HX%/'IE47 3O"TZI4B L<(7'
M@_OWA3CJ%4\*Y!_G?__;63^"CM Y4 V/\?>%?A2%C7)YU)5^23&W="\>R]!0
MKE:JE6+%*=:<@NT>JV(T#IE*Q_2HZI:$O"\G+7,&!2((XD$Z9#@<EO14.,R+
M9!G'E:%3$7HQR=UDW,CGP4-NV+"F!SGU>KVL6Y.N,SW3":J52JV,S5VJ6-)=
M!C37FSYRCT?C+A?*Y4 SIDJN&.!2G,I)I98BI/@\=& *I_S[Y\N.VV<#6N2!
MBBC 2&D6R86HU<O0FG3D2AQ6G7=+UF%[I -&B_HZT#> 5;/?/]Q>3KI'\_M/
MNI8C20/5$W) (Y BA'14K%2+U>,,D"+(2 Y0(C-/P3G)" 5.SI<M=8J*V.I-
MR:KM?%PVC;;K8HE!N2]H!6#4PW\C'OGL_*3XRUG9?(3O!BRB!"$4V9\Q?WQ?
M:(H@8D%4O ,Q+1#7/+TO1&P4E35$4L9Q90N4$'+6%=X8/YYY_)&H:.RS]P6/
MJ]"G8]0&5C@G9WS4P!%,VL_<\UA@/D.7*Z,*)* #',MXXV+  @_^CS[Y]-[B
M,8IN60^:8ZG)_ <*+)*Y4OLC$IFGPGF/^HJ=E7/ 9R;CWOO"/S4>?\",?[0"
M(,JX"5-*ZK<#CXU^8>-"!J4%'=9$K0+J<P3\J3BS^)6G*"-9CTFMH/",6MU0
M6NE@+J(-0@.-R?N"XH/01]G1W_4EH@)*7TPTNC127M)*I2L%<FAE\_$*ANG\
MK)Q?CEU\;L'Z68E8FD>M0@U+;<V\%:B=#&.:=^DC]_"+'F>2:!387 5OMG_)
M\VMZ,&(]%WX(#!5>^@BZ+:./-&+G$]R2D9.V":[>@KY)2SIM.D\Y1YV4FA/J
ME;,*6 9%/<^I*XXJ4I_?!PT7UL)D(=\^Y%[4;YR4CGAPFNGKLUYT.J#RG@=%
M_-P@-(Y$\HWD]WW[%8(+$V!H-HM]IEO!;X<IB$B$C<QC5T21&.AOND("ZLDW
M3C@B2OC<(]]5])_"^8_?.<>5T[-RN&BBVM,359\]40;L(0 ALPL@/6!-4?'_
ML89SDC[WZ(#[X\8='S!%KMB0W(H!#4YUV]#@W16^=SJ'/;]>M>]:'TGG[N*N
MU5F,3F5+Z'1:S5]OVW?M5H=<7'TDK=^;_[RX^KE%FM>?/[<[G?;UU8MPK&X"
MQ]^HZD-T&(G@@'PL-4ND6CDZK$_A-9FTOH)@YN7A*86:*YC'SQ+,4@6ZY67S
MU"AIU?EA=O$K*NED,8F-F,>O^I9DZM/U[6=RID(:I&:HSR-6A&]<!IYS*&D(
MKF11"/%1N#%&$)E(9G4WK:.DO'\^*R,JYV_R\@KRLA']!@MTV[JZ([>MF^O;
MN]W;FYM8JI@&$8D$Z3 7)<X0S*D1(8ESM.?M[QY+T2-1GR&"L>01A_&MD=NG
MP3TC%VY$H-FIUPX7X[DM[F+D@]A(%@H9D;WDF5&(?)B*"'N$GK:9>?N-Q<E%
M8AEN=/C4,E'5NB:"F'SO?0%RQ(8'  8PO._1\1@P8D'A_"*^CU5D.%X[(#AT
MUJ2\V9)-VY+JX2:D;;'PF#3PEMUSA6E_= 4M:[N7BW^W/[;O_D,^M*\[S7;K
MJMGJ')#V5;,T)RE\@8&H;((4>ZT1!4. %##ZEZR<4$54R%S,A3S" \(C1<!T
M@/K):</V)MKS1?L%=,&*#NWZC+C,]S$FTI7/2D$_A]3SDF<[E5VJ*WR?AHHU
MD@_+)20C3AC4&6(XE<H/EG2-BD6S44DR/41,FG^\? )9._P!<__(FVI]9#+B
M+O4M<<V"Y_:T<*IKP$EPGC]D&B#\97&729>0WK-B5S+Z@-5.2/\;]%& @*Q,
M.$>S+C\OR0@3R4E30\L1F5H+R 1@F V&IW5W22AL;%8[<(4$[ZB-4R<"E]44
M<1#)<5-X+W)_6"+%0D;$0BD><5KT?Q^93X?@"A?&T:N*02+S,_U?A8;/SC<,
MD3]QGT%;%TS3^J5!IUBKU^:%"99BWS+A[NBH;2MKKJ;4,ZEX>%QT:K7C^G%E
M!3*^AK:?;$C9G^OU-Y)[[VG[@&F*@.Q DO]"<J \KI,8B +6BDJ<5\"/9VV9
M1E/>TX#_3S_O&U>[&S79+=N:8C#@"O=$=\XBM(3$*/%?F"'MTFVI4R*M0>B+
M,9,[YTK>QI(K49HP1UM#^ NCRN=G^QM).IYP%A>>)YE2]I]+B/N=M1V%4ZF_
M.R)7)7(GI&1C<@-0%*!(O6G'<?!4-CB+3G5M=#HQN$SB',UQ6[O. %=;?1,^
M7LL[,0S67OLE)?_";.2YA-?.ZEK>0/3)]2[ZIF/9)A $.@5\!L45,;P1 -/_
M/QX^)]8^KU<KM7>;E(O-V#:[-JP*A!((ST/J$S9B;ASQ1RP6@)EA:I_LP;H)
M+GQ)N7/GA@7%]P+"OF<Q:._DZ&1_5C2>'1)?"G!B-WT1/#>7.(1<XEV]LC@&
MWK7L3 IH/WYW4G7>G2IP[CX+<<TDT(L^("!3?NPQ EDD!0I\$0)T5;[8/?4^
M@<&"J/Q*U^0DL8]6'X%N/=+4)7R/=- @DDNJ(G*K2^-OE;G7V,!Z2K3 A?29
M^Z"W6F@(K@4,)B9873$B7>:+(?(,&Y&53QL.O3VI-9GT.!#WGG %VA*QP .>
M1X(H/HC]B 9,Q,H?$P7V0O7&>@8[0'2!7#9],E-G*KLQP)&$!N.DK0?N60QQ
M'+I%C@F&:BR4I.-GUS(W5:MT)J=&&I5,U7*V.CI5/5VM&C"=X)L)#G\XG5LX
M663E?Y,\ I9ASA8'-B)7+PY>ND+X70KLBD"XD,KU=X>'I[..X*EL;#IY(GF.
MDA=;VZF#1(5S2P\@0)8@),SLH][&("2'U2,KH5,[E[AAN>>\(\U/MZ1:JY2@
MX]/9S9O8KBFV'3#"+A \N/\,)@SLF/\7EMD),0"TH<:LP#YISYU#6G2JB4F?
MR'9N*SZ1[">A50\K)0-Q/Q/OO2G!)I7@1C*TVWA851\R0L\KKWN]]6/U;T@9
MGI1,H%K1S9 MD?BG+/X*"N05JWO=_<VJD('YID1;4J*V4C&3;ZJT8U6JL>+A
MGKM95;(P5U:E#'W-\;&7IE^9*-'D.4Q"IA0N/**'BI\D/[#<Q;F.1N_MX,8W
M>7#C.5NY*]0M%JQVCN[L=*OH#B^)F2.6;I^X/E5J6_MXSR7BCG?[[B1%Y=WY
M)E]G/("F/;6U?=>OE%]7]DRC%G!FO=O.N2<" K8 ,)HXJKR__-:.IUG?/':J
M76USUM[MP" 2J-:)A/MP0$(JR2/U8T:^KY3P_AX)\:)?_^L[B[:(8-;.&#5?
MFUJW5Q??"!T2P4D"T^><Q9[)&= .)/N^=Q#]75'ET3_)S[Z 3()\IO*!1<OH
MM[60MAUX&.8STAT35^\N ,0'L!U,']F:*NES18#&D"K@I/?D7HIAU,=L(<0R
M/U7$8ST>F(/<ILI:.2*SET,F=T)J9 ^EX-VIKK0FG;D^ A[B$7#<F5HQY:AV
MBVGU:[4+*4\#3;##]&,&?@;-TF*#OQD^M>;3W*B05:3EAP@2"#]K $TS_E62
MX^,YR?'K4J?=6R*7N 4\5\CYS)95'T28^9##@0@'0F=TL6*Z%]#(;HSA>QJX
MWO,R5Z>1)GHN?XR3#SE,C>H0 '[0(MDC5S .%(,&+I9VJ>OBF6GLC&]L\*CT
ME-D2\Y:FD[4]FJ:367$NK2,%H[L4?W-U:6OUD46Y[RJ7MS=S.?M+O05N]HWM
M[O'?_P:^<*ZJL,&,IN!7F=BMRX Y$+OY0SI6!7/Q!U_>D<9YD/8+V?BNKO^<
M)@L*1[GB7EF_DT/CL7QS?K.W^V'2Z0KFA^O;CZW;8O/Z\O+BIM-J)!^^[ JF
MX\PM81+]$61IMC8W&ZZT(S8P G)2PM=&S(1666"[*C@N2T3,*J]U%-'"6Y6J
M1-:IV!UOPB]<!V3.#<H#<F'>7D0^3%Y?=$#:@5O"<.2D6JV<VA[ZR3E%.XY6
MUS8V$^>K&_>)5@<=]8#-!J[J:N=0FAT]>B^9+JZ2O0R(7[-=+I(N*43M1)IB
MR * YY%FXLDN+YL'I//O#^22@54-'LP70%_I@N(3\.UQ2"Y+E_AF ASX&THU
M^01D%)E@R,*A6,8,)5,P,\73=BKQ+HH!1/!4Z4*85-J5>-@L&81W>UA!1/?T
MR'Q ;-[28%"RH .8R:=ZL4 B[,P5>CF7:305-46BDP.PC/B_R;12?#($UZ>\
M7).KJ2=SM1S-LQE>@EB)8'@>@H=B"69AW/7QU3Z!"?$$;B+8TS'?.Z"-E0EX
M,SJ[8 @A'IGAN3Y# ]X<'+6-(>RB>E(,LLO*N?PH"S G'(3"?Q95H,OWSG&I
M7IW&)6 1AA(N3*\2<,DT=M[LFI!$;!2:B >Z=^W)HA''C6A_#+/4CDH5HSZ@
M8S['%U^ -DSW.CHJU7*]DNAJ6AJ ?T2$.GS*D@<M,7X)0F>I!&BR$<BU#IZ
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M(N2!I< EC?K4YC@_TD%X2GZCT0,JY^7ES4RXZ+-[6'Z4 IH;/F8=32*"65=
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MS(YV#5$9&%4HRI;JX-,I@OX(AYGFT_5R4N+YQ<K-L/P"9IY68/E.%TFVQ &
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ME7%>9N5AL3"LV&YLZ;@/F9DN0A$;--J^^$,0Q!B/;!2#(SI1CY,:='_OR-[
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M JP1MG8T3T J'[DWQ0:K2^0PC1+8,BCX+HNIZ'B,V\?(<FA>P?5S-DY.+M=
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MS1-+PLP^JYE1CAD[$OP0D@W((:=&,AXY3;!X\E+RY8)\M*&F +=0JJFS\Z+
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M2I6U[G0U&^7E@1.SXAT(IF'O-:4_R)KEDADP)/:'. \:'/ ,F9-<KJH!BB"
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MA%;/EJMB7+.!Y"NNMD=<);#F*MH6"\Y/MYW_(#"9"<=.2!_&6GKM>(G!943
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MY;8V>B6PA/\>)S]X++L!VOXFT%VU:"SF;H/5--G;;3B-XEV;@W.@8W.NUZA
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M2I^PP:HSF_ZD0'?JRLZ+^<=Z=FX+1PSF;J:,U<E6(+3<=I8) #2R6K.+QJ.
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M H2==,L,3I?ID1+C.V-Z^&8M&#8.2R'&@1\:L<CBV,?XTT\7V039$?^\UL;
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MM+NB@5AZSQI;?,))JM-:VP6A4H00G[V4[B$!VE@%-\(C^/)2;[#[CPG&-_:
MY!S(<*<>6I+#^%"U+;5MU1IJ:WK\:IV?3[\Y/_]:"-^FQ:39B%Y7$;@@*Q#R
M$."GH_,*V8B@UXB=CP_#>RLF6MB> %D,QW#&"$GN.3D!@?T@SZ?0\J+ ]AXE
MJ$PTFVFR2+!#<*N,V.KS.2R42WD1F%W;$A,,*T%7KK53\KHD>7..O\WQ(F)2
MP93%+ZMHQ$ZG(/!B"W*)1A5SNVA+9M=LV\&"R]=V^5PSP\LU&0)TT*PF?B$%
M)]@PXP$F/@G 24,9[3VD. !R;W1S%T/&(0I;-'*72Y)<(9)$U[>*%HD:NN+K
M4F+( ");,R<Z+%(9CP1TF&&9';)D+V!Y>]MW0^GHA*45D=[J3QP$'6G^\A/.
MZ4E8+Q9]4E<0NQX_ FB'&%$YO)A=56VQ'@>]7<3JE65ZB4_>G5Z1W^F<_&SZ
M]!:(\V/$07LA\C8$>^\@9=66+;D+K"K:QMS]8Q=3=UP"3@/DKM7[@MK"!'D^
MB<C;I'+)/=AN96G:YS&3@0<%)+=V9HFWU+E IVSU2@R@.%Q^O$X7SC2G&C&3
M[[%Q2^]!&'NP0QIH,U(7NUR!Y:9.PV/!0=#\0F&(K9Q8+M44\V^17,6DSJQ1
MI2S7U,NP].!T!")')F]CE#1/D&5@0 %XB6C;G%XNV!$!<Z8K0J-BD "K5J=T
M;R;%[%I\;ZS/2E(]'9&'5"_;I=J*&0?G^<<Z%]Y/O PD&.?DBQR0/]CMRFPT
M3Q 17&<Z3V?LE"ZDN8]*&*J#7Z54.A<TZ>I)K+_50@C%3V[,XMK>F<6U<"^R
MK0IJLT'/;'K<<CJ.(O9PI'M ZH.]Q("*T;T.O&@F='W:,A*W[<)KO3GCT4R&
M%:QR/4WG(<CR#L%FTN] M0"K("H3K?\@XUZQ S'!.X2EU!%([INB>R%!]I]J
M6RX*K$Z+\QPV<<9>+FP9B$EG^K[S)-<T/L5X$TE+ZD7FT2;9"Q,B67%U!_IX
MB"+8V?3XV3;U#J$ZE(NM;R=D][/5,D;PZ#,JZ)$RD@J+^K/%0J^(0#<$*D_N
M1O"=:E@V4VH[)? ["D_PJRJC[+?U2HYY-[[]B2KSZ"S9;1SI/;A3@PW WE U
M?@OAZ3,N5D,G'H_"JQ0T!)*JMI],'VB/IMF_Q^;&-'FO.&-9!!G.2!78G95&
M10BVRKG;?A;F7;XML&@8KETRLVX_Q-NDFB5_CD>_+HH)8D81U$#$>ZW?1O)E
MX]-#L1+D8&1V;_]]>A2]^9^SZ/7K0^, VI@"LO$!%,L/8*@'%,/!6( T>N.L
MD:5,+MP34B9[L>,16HCP%3YY9];?/=\;D@4M< F:PA*[8N 3G^A/@F^M["<E
MK6C.[LUIFP#!VM$&:>E,H3*X]8K9#LE5H1/N\(M/.GZR=/0@0H+YH=&C2'MJ
MV<&<XUVC&YBL(ZNY6 ]\$DV2_",^@9 K,& &JVUN(QC1BT3L\U>L)T6J)KE\
M<FV FWC5'\SU<LT-L9#16[E*K0-+LJYT D708 +,GWKA*E.FBS0I.=&$>[ Z
MQ.T/.5UPBHA4H=^^^6U7993'X;@H0+PNN.^7WC^M<2;6C[HTI^2D90D+KI;Z
M7)FVM@Q;>:UK<EJ1![B,P/9*%J[OJWF;L6$[%M3_!CD6#V[B.WK"OI5.O0:C
MWR,0V.T@B^^RPZ<1LFYNJ(P]D]6B$VO..SK4CH9-S8ME-HU!]N+BIDPHWI(V
M$8:=PG8\)X<'WFRWAC 8$?K9^59TTX"/<^'$=T.;L\^&;0&N8V.:^VN=]GO?
MOT9W\;-O[N(OU?*D!TFU+^1/E;1)]-9T+/A)?XKD?N +FZ5KD+L=[DT4=NQ(
M20(KPI202BV; Y . 5;O;SL03.I'1D2) 1;/8'-.ENC8?9'C\2C(L4RIA:3'
M*SK'%SOH["U\CIT)$R'4&PDN8],)U\G*QMM,,W9T3XA0$Z.0])46A%Q7PDAW
M%1.R8D$)(2<FUOA)M9CX@VD>Z-G6'DL(:!BVQG!T9#NG_6HUI@.KQ<P[NMG?
M \H;[*5QTZ9;SG2KMB%3= @*G>(V:FV)3R?8NNV59!II]A%-WW;"<LEGFJX3
MNWY?89JJ*(O7W:W6[\%Q#39<.,7 5)V4SKK=,O%J<RU00NEHO8.W4A!N7*DS
M5+W )[2N8$LQ;*2/<"+AW(-D#7?ONP>'-]@BHB\7K76&[TS7WK;/I!<!"=$-
MZ8=!DFA]6X+H2L2KN])@,?WL_V_O2WO;QK*TOPO0?R!ZI@$;8%Q>XJPU ;PH
MB682Q["=RA0&_8&2*)M=M.@F*3M^?_U[MKOR4I)W.^W^T!7;$GF7<\\]Z_,H
MZ[56266G/J\Y9[^.LUE%#L].K/+Q^54W ?-6\3D:E@N3JHNDY-3B'&^TLUCU
MI+],G^-,9@/+%-N5YAHMDG.JM!:0,ZYJ#G8A*KI-!S_+1K.]XOU_+=#U&RTL
M]MBKGJM8=5@@%[@RN=0MI*>'TX)/HW$\*,Z9\#.OT@ORJ9OU>]I#'>$O%!1%
M$T>&:R-]J#%0&7B_DA;GMIE;U> S!7OMS6V X+UN!<'K&V"[KWO]C_T=@J[S
MD?"V]G;UKPQLWM%!?_N[_?%'<$1GHJ+UX:FG$\/]!EOK7*4N?%R;49#)4]C*
M)SI <+U.D95.Z.L= '^'V\NVK6++X&+=2O]*D1H8F\*$Y[Z*G?)5A6U.&,2"
MY8GO9*8O TIT<<+ )&615Y''*M#2FN74U*]MMG1K%:7[P?55C9UEH^I'2\CE
MS)>=L#CIKA=[*'I/X%CN)R6^!GM@' XEG%\R6>S[EW8'37*,N"RU+JR*L0@C
M.\4K^91Q,1A?E*J$LF2  4+,C"=U52 @(\7,F+Y-7616T3$56IE2;M0*#B-T
M,5Y6;-@4:B6$1ZK?EKZ7J2LKS;F()4*14PF-QC,I1BTF29AX,4;H:KDF9LT_
M-K./6^=J5:V#N02.&MHOTUJBK:!O!PEV)E&3Z-*6!=C>Q,1!6KT\/28&DA"B
MD8Y\$MB-8\G@ V^>WCA**81"&8X?^++*2W#LV-XL%26#L70#C@:3;L[XDY9]
M)*+.P1[*Q#J(2?S[)E+>QL;2:';:>#YFC$<F*^MK QXAUL#-"&6M!ZM]E0I'
MTW%D8)0-''I%@&]%:6YF"WW;-9JN"X'N\G^;G@;:;@3+)JQL&FL0HIW@2YTA
M/]F8\.OGF/!MEA![2+1+JOX6)%4X.<ED5<CX&,%9CI;T#?=52ZXJH:^L>XU.
MQ=*VE78KK"R[4JV%A=K)!5974Y\SZ<>OH4!OQ'%S;_H3BRL74J!-O+@V%7IC
M2F[[P0')B!LWYES,O2#@'JCZ^8A[)IM@^*M\HS=@R(#B/CVK%0@F_)5Z8<6Z
M:F=A8<@Q0JU7UHW!A+?\+4U5,Y FPMFC<>Z+;H?+ZXVY(\B"FDV%6-9@4R9<
MP,#_I'N"[4M%6)ORIZE2' SL<D30LM3Y.A'.:F4@4IRG=)@$6\EV8E/<<)M&
M' >].(30H 5@+Y>'9%@.8G!W+M".#3 XF^K\04HCR;7",071+C$"UZ@O,C?7
M0)]C? 9A&+5>['8:?Y03-E.)ZL:(61C25](4>N)S=,6BX)4MVD%AK&-"04(=
MLDI*UE"19K4T:*M$@VV=-0*>IE^7.T)#P:4!U4(XK;Z^&RJ-_W3[D3*85I;.
M$YYL!W^/P9K1X1$]2OD0W']5>!:@9%(Q^;YYU&VTSEW)(L P@@0.ZDN3Q=&Q
M*L>E?KV4+!-4)],8(7S .:O&C)2(@K,V\/6X:-V.[<(***=!VB<03XHK!NE4
M7.?1:'D< ZTM:VI\BC2P(+ Q)ISI5>BH&F4&&B Y3[*<E$#H=41HG2=B6ZN6
M#F$=GJF['T&,:28$<2#&I+8@P$K",:9>(V@DP0(I-<<]H#A"CGB#<Z-0P4RT
M%78B3@35FH]QH@KL9,E0S ! F1]FLM_[P"$F-8R6\%(CNC3_F_<;6'*"+=<*
M++7.X[$&E1K7.DS<#2IE=QE4>E3>2;=SP_#.C;P3]B^=NLXK.9@W6$HN:7Y4
MD;(;+N5"OADIMYG.V2)HZ(,I&12F=(<25P&;&W^^V@&:8QU?)-K.C*YB9J)N
MNWT[L^$!WIVA&<VV,\/^<FU1S(5N*.T8L_N[L.?+,#)-#S=J.K@M_FW0O6UX
MMRV^K?_"H&?7[:AKXHK>:K28LXH9NZP*V]HAB_HBTQ@]VJQ^LD'<-\]!W-L,
MXHH_$G*K7'A6)DC0[@]Y60_F0EF*L]L):)>'AXUIYV+85V%"!?<T3+.SFEMQ
MM,N#<V'E8ZV+ZT 3)( FM>+*+FR 49V,$HQ0>J<VWKGU=-H]=G58>04RO*A4
M^")G C[M%Q@'#97FG.$27P;Z<E(ZU?BF78,;G@[>>6 \T5-G!^S&(%78VE 7
MZJWV]*V7&NG%*ST])PP! Q#BG0KX&TJP'V%P)QHF2)6^5.JRL9K&X'[ZYW24
M#:W+3<9.GEML9DG@>+@C,Z<9WI3KSY+40T!N/&B)UL58B?IC*PIH-[D/$% 2
M39XZ)%+Z54+0F]5F%C/V4Q<8SMQO!+3"FO*<;1PR@X;965*;A"XM?L"LS+!%
M&.RW*E;A"F,(L 53@1K,DS*_Y*%FY'[Y Z%G)V#\GPHZ%!HD@K)B5DK"]JJR
M:DXQ87.7EGA#-2JV6D -T*73R"HDZI$D-W<#U\Z#]F_.;GDEVB+E)NI)5\J'
M=JPQ> :(TW UE$$4%VSNBMG08SKA;I/[SCP=)JK?NJ0LZ=Z)GV?+&@"Z1AXG
M./.67']XRI'5S6YEF9@HF3K@+(.S76URC4'P?A!5@,6]9 5@2)8JMZ**J=&-
M2-C9$!F><)#:ATR"9F8^PO8@WT ?C]1;B,G9P7E?NLK<E\WI%_VI(UAC]U:R
MMYNBC4MVG(#G;CQ@^+96[8X7IDB1. "C+C<W;4Z1KUI591?F'AZ3S>,&6D/"
MAW%T\=Y]M_&F3QXL<U=OV^(TND>QE=$@Z&HU(==5J:K.(Z*H*[L= B3F0R.R
M4%D6(1:=" T8HSQE8TH:R]55.)R7=& 16M3Y?OC$J]B/O:D!O8";BC<L7Q)S
M50]+*I^+.1J;S.ZP?I&8<F*+LR"9HDXFCF-;M;::2JE6#V6;XAL5*;N+([C^
MCUD[B8]L?9]?1],_,XC&>A6H\EWNF81^;#M,W8Y<B%7;@*Q3HBY;TO[5+)73
M/,MMNSY7_S?U7'C7"3.\<;HL:\PL:+=SC145PKUL,DU-W&+95?IV,*CE?*J.
MAUEV$-KZR!V$<H:*X<I76,N[,1F[^!W6<BW-WJZX+2"#ZL59J])(#=XM;E.9
MV&OLK7+OD*)SDRVNDE.WBY'"^.2H3/5IHP\=*Q8"BAXJW)C2912,+3M#%<M;
MISUXZQGH=IJ<F@VQ5J#P@1M;3M++*I*;G!3%F,.8X2W*B#S#3;1RJF=(C?)T
MN)95Y)!>9+488#I-M96;BRW<P9&%;4D<0+L3A89H5FDO=G:M2U%ZM^JMO'-&
M]))0;0Q3?0.M_37X_RS R2F"B\#++VES!VTN6M"N5&E00H+EV+<V4U6$%J[H
MGW*/64)D%17YHM1BO;MJP[@S^JO9I%D_A+7ABP58[Z5^*!ACC>W\&\%^4":/
MX*8N5;8-4:QIIQ"C,*,WV& A-DH3P1FGQP5Q?NX5K2J*V0@*L66Y-VI!-XO@
M0OC]-&(0Q!+S$/(3?U<YIY.:82$T^L23#>V^?0[MWF9HU^]9)$1_.95T[6@\
M?7-/$C(J>0DFD1^[AU+GDKPB$,8;*;,!0WL-":P0LW\<XVE7NTL><"^=L9#F
M)C8GIADL+-Q"_7?)1R['RFVCB\^<X[CE)&GO3C2ML!QKL!CB9,U3,?0H]1@R
M>*[8+]=F)'-<#A226PQHF1N>;</[Y<+G:=->I@3:UF0Z&;V&=ANN?YWS1!;G
M:8ZK-,W/U*OQ4[9EB^G=EK*WQER\6])I._1QV[H=W(J4,)HG[4K5,YV:.OHZ
M B[.1B6P08*_@XN-;JROLW50C7]THD=(7:\W'!]RDN9R'^;)93I:E@3V6$8^
M4H6YS?>0(\5N-+](QQCFO82R)6/QN#'88:X&S8T!*P!G9SQV C;,A--J>%.6
ML>)>D/;"K' <2;-PB#G -1 *"-Q(^D!52FLY=S&[U$Q6P"K3IBOG+RS#-QBR
M=N!1J M884:&+3(GEQV:$@QGEH$5-S,=*KZG5E)\W)!D,RZ>+=TX"H&7]8$.
MFA&AA2095DVK/G^M\31,F"4/)*6P'!#LBK]\,<;D\M++3:5OD#BJD=!BCJ[
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ME6;!!8'">,(6"7S[Q(R[LKPTT%0DB6*@6?V**V)6WKW$M<-VJ4+:[T>?OX'
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M@D&D2:!P S.83B*$N59UG.1L-(,TDTXS$9#R(R8CY5)0X9#IE,(G9"0FLR3
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M9B_=[CEA@B=[H;03P"KH@J1<K#FV(1P55IE;&I=87](C<TNGH]9[&D4?/C<
M<3S%&W-:EO!FY*HA424Z.N)4FG7N_+.&,D$R,.^@Y6FBO@!31O9U83LR>QVI
MK89;QQAAUS-XKF7=WRBU?42&:E67F; Q5REQ7,*!4=PEJ A&%@.J1:<("A\W
MX!T:*6WC?G474;6EM>6V&I3,XX_W9#&)"-H%Z8_AUX4<*JV6F20QH$8T)S<Y
M% ,0FF@,!G^W<YR-2>;POY62QM,4T0?4Z<Q.X>+/"'J<Y@,/0WD<,T4T<K]H
M-\]ZI456#>,A U<8SYC=&^Y3I&1$+:&]HE&:U">!9Y'J4<33.$:D):EJRQL#
M-5YF;.\8[T03CN>-!>EVD#N-IED%7LBLO-5"4U>*<5EO8'#?:,3D^<N_BS+F
M?X"GMH2IP'EG;EB\D,\O:W3#TIJ_9@KFQ4&6'B%>KVKC\70[WC?(L*&OO)]Q
M?N_F'*S/.@?!9;3B2A2>J.56C]F,A8^![A4FU*&4LRJO!*8.XC !J2/"S/K2
M/SW*-L*+@YUM_8Y(RXNRRLF@X,B0LIY2N''K2Z;UP\!]-FDX?K$R0X?(R\1F
M*!A3X]AP;B/U./PQ5CLCQA+?1'3!44AF)L_QW6S7QKUN5S1SM[J=N;JN)3):
M)6PWR$N4+K16>D)[.CG.W8)FW&M68]5T@!1;-1N/],M6'3),SL"]RJV0FEH$
M+2A@3HLN<GYK!ND*& :V]!=#XB2L=E<<*#CZ*3[1%T02._H\\S\K%DQ%_X7+
M@@D193PX%W)VRK%)VB>'9PRUYL#2Z4S(V2XQW<[51089!/,":>LKT8R\Q:!R
M43PGQEA;[%*3:-@C.Y8O6X^E);V5$S?V+6[-%GUSN[O;X:=JKP;DJ3@#N8%)
M_@7FF3,F=E6(=S(U'*@FHAI'O_<_*.8Y@JLC@WA26+L@IS/#&<HKR?"F<X"!
M58Z+$T$D>RDCXWFJ5-;+F/^[Z<2PEJW()&SIM:SB^[]5-]OE@;FB2]"E3<4)
MNH0#CA3P8(9:VA\KLCHS:AIKPMDR$?9!.&*\>_BC4ARL@+W(5&@\XNG:3SM-
MT[H2-4.;3>33^+0#Y(V8NT5KJX/-%VM@3*I-,J&FGL@SND2@;3S!(TD\ 3?Z
M'.FN\&>21!)#&MFH2%D5R+=PNB2"9TA_+DS&:NJX2L[T;^Q\,2%RH9) 2M25
MJD4UQ\21YT4^G=1@+L.!H"N4O$,^.)@B.TY*6FYK9C<=V_NG2P3^#(]YBXKI
M5:MB6LR+]=K4,.T -UHU!HNH3GZ2A8=F.T66X!0<J\CRM*RFR:3VOJ_L'FVU
MXZ8CJ1T*?>4%8BIJ@,O)EI'0@FG0=8P'^6M812X_@'GP>L%5MY<)+?=I6;-N
MH!A]46*4BE. )7E&2?2O*0@3LH^#\H.WUIA\IN0K!V-]XSO!S,9Y40XQ+%/7
M'&V__^OQS8+KX4F;LSQ$5,W9+U@#)V('$Q<&<"MS2<3BGM PARY?%I6^',OT
M3- ;?=YUU.)%.4XSPO9MM^/OT+:3A[8X5L@SGTTL+GLW':3&A_3T2._@KN_]
MR\';!>5 AZ=<,S6Q7<>3K!R]D(@NII2(29Z2I:=I>8S_Q:0L0C[(\OB>G67)
MQAB9!+$P"0%/86T7<$7C$!1Z-?J/J#)1,L'%X]!%9477[6];@I!-P!@X1P4%
MYYUM'_@."7:1>U]W+''B)N?4O:@[,(MTEHA-<UJ&Z-JKH!PK670R3WVCZ793
M!=%)F@=S,!PR!E,S@<F"1_U/2<3XSB[L^<0XAEXH&J8SUWC*T7B::N/)JA##
ML2J2>JF"B"5UT]@X3MC(J$]3R9J%DVXWW*1EVO]BDDIJ4 5*2JI:41%9<CSQ
M^K8\/XF$<A2; M"JNDJ[Y"/Y:Q6[94I.0(5"9^Q%.GZY1,\6>GYT0<D3/#;1
M*76Q8ZIQ<_7OZ@@4TUHSJI\7=*/;"4+WH% PEVS]*>@Y.ET<C%B&RQ^-]+LN
M@5K,<5G:,E$R'4 R_AO+"EQ,PS(;L%4SS*DX96D-=GUI?1E<I*4-2FMK"X-(
M24$D:A$^S+"C-(TRE0UT)%'73UEAF92HA:4\0&H=]57<J&1)-/\BLRXV_%-*
M5:,:00F4'#*FE'6<""N#N'JF+GP)2G1%36)<W&R""LZ.JN$+Q](W[<6XEK):
MRC99G]18>473QF4N4YPS%E#BR_DT^QD'.<RR248CR#J1OG*&#6O(BY_^Q,6J
M<GD/3)NR7>&43DNH"U>.O]+MM'W'O)@+.4U-"AOGR9!LQVS"B\01-%H_8P,T
M-Q8^M;1]4PF-0$#A_U[B_[W"_WO-\OK&E==6K[G;F>$V>YZR&=&M>/+A@+H=
MX(*AX?$">Q$SZAS&.&23C&>W]FHIT4%,)[@A7^*+'QXWE1MW8B6'<K=BHJ6>
M"%9S9AT%!9)O\8J>^;[KKWRWPTO?K-/CL\154[C<E2Z")UN DO"T 2K7QJ8_
MVT8ZDSM+@FV_P@BP(Z"-B#/K%!)#2NBJ+.Z<3*M=-,1#ZG86'M/ZXF.BJ_TN
MLVA\1-A 3,PH=! ^MBM5FHMO"IF",]U8?*;@C*%I]&123D[JZ"HYI^@.4TY7
M3@5=(WF(,6RNI'&R/M=*\:!TG;O"]53CFR^?XYLW*=1=6'F^NI+RE*AF-".H
M"3)X?LW+Q;76E;L>'LS=QP2C9D@0YW;=F_/-P@N-JG#!,%9(=7&7A4JOJ!@;
M1;;8>8$Y7/_Z-_9KR,'2CI-89>'0!,ZC:CHE*]W.1SN:H#Z@2^3BV:Z(%5>
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MZI6RXIU:BQNSDKAI.+EX\^[53J(72UPU.#T9?UIJ7Z>"-!.#O=.3P=[U246
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MF'RSVC3J1\O'#\YW_+6R]=Z[?F=H?WQI6%6+QV\_61$$TR.2OWMX!;/!0T,
MAJ4G>X=/J-Q-:&4DKA2Q/$*%4]I_?Y<_-ANU7TOJR*R.1_V1I=43G'K'N/]O
M2O[JIF2Y7/V";D)@6K07Y3&"!L084:$TR DO8LV_9WALM\\UAZ!DARF<Z5>T
M<DGA:;855!YF[ >;$FDXW9R\@9Z)$09E-Y'EKU]YRL>8[ZWN@0T&BHUI6R"
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M58WY*ZJ%D,O9XOU7[XI:2J[@WUK*6#_>]\!(+DZ^X"'_=;5_ U!+ P04
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MAP!_A28R^1MX*)._/HF%O2,#)N9M7)1W7*DM_3N/\ETT^\T_:L__4$L#!!0
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MW+PV<B++$GWE099XMA3_@ZV6JV O+_=88-ZPWIPQ'^9]82SY"U!+ 0(4 Q0
M   ( -2!!%-ZF9SU2A0  (%\   .              "  0    !D,3<Q.3DQ
M9#AK+FAT;5!+ 0(4 Q0    ( -2!!%-RXV["$K8  ,*S P 0
M  "  784  !D,3<Q.3DQ9&5X,3$N:'1M4$L! A0#%     @ U($$4[WI9\]O
M"P  -#$  !               ( !MLH  &0Q-S$Y.3%D97@U,2YH=&U02P$"
M% ,4    " #4@013K"[*_1 -  #M)   $0              @ %3U@  9#$W
M,3DY,61E>#DY,2YH=&U02P$"% ,4    " #4@013"U-$J6,-  "U)@  $0
M            @ &2XP  9#$W,3DY,61E>#DY,BYH=&U02P$"% ,4    " #4
M@0138,\%@%$#  "5"P  $               @ $D\0  <FYA+3(P,C$P.# S
M+GAS9%!+ 0(4 Q0    ( -2!!%.C EMPL 8  #I*   4              "
M :/T  !R;F$M,C R,3 X,#-?;&%B+GAM;%!+ 0(4 Q0    ( -2!!%/DK\*P
MY00  *@N   4              "  87[  !R;F$M,C R,3 X,#-?<')E+GAM
7;%!+!08     "  ( /@!  "<  $    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
